

Emergency Medicine Reports

Practical, Evidence-Based Reviews in Emergency Care

Volume 35, Number 1 / January 5, 2014

www.emreports.com

Authors:

Michael P. Wilson, MD, PhD, FAAEM, Attending Physician, University of California–San Diego Department of Emergency Medicine, Director, Department of Emergency Medicine Behavioral Emergencies Research (DEMBER) Lab, University of California–San Diego Health System.

Kimberly Nordstrom, MD, JD, Assistant Professor, University of Colorado, Denver; Psychiatric Emergency Service, Denver Health Medical Center, Denver, CO.

Scott L. Zeller, MD, Chief, Psychiatric Emergency Services, Alameda Health System, Oakland, CA.

Peer Reviewer:

Jonathan Glauser, MD, Associate Professor of Emergency Medicine, Case Western Reserve University, Cleveland, OH.

Statement of Financial Disclosure

To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Dr. Farel (CME question reviewer) owns stock in Johnson & Johnson. Dr. Schneider (editor) is a retained consultant for Logical Images. Dr. Nordstrom (author) serves on the advisory board for Teva, but the product is not discussed in this paper. Dr. Stapczynski (editor), Dr. Wilson (author), Dr. Zeller (author), Dr. Glauser (peer reviewer), Ms. Mark (executive editor), and Ms. Hamlin (managing editor) report no financial relationships with companies related to the field of study covered by this CME activity.

AHC Media

Practical Management of the Suicidal Patient in the Emergency Department

Many of us have known someone, a relative, a colleague perhaps, who has attempted or died by suicide. Most of the time these tragedies come as a surprise. There are often few indicators that the person was contemplating taking his or her life.

It is often difficult to determine which patients are suicidal, especially if they are really intent on dying, and those who are simply making statements to attract attention. The new Joint Commission standard calls for extended if not universal screening for suicide ideology. Their intention is well-meaning; the literature suggests that many patients who later attempt suicide come to the emergency department (ED). However, many of these patients come to the ED for non-mental health reasons. Further, with more than 100 million visits per year, the ED simply sees a lot of patients and could theoretically be used to screen for anything.

Screening is one thing, but there then needs to be a plan for patients who screen positive. Current mental health resources are completely overwhelmed in most communities, particularly for the uninsured and those without adequate coverage. Adding more patients to a system that is already overflowing into our emergency departments will jeopardize care for many.

Finally, mental health procedures are legally more complex than physical health issues. Clearly there are legal implications if we discharge a patient who later harms himself. There are also implications, legally and emotionally, if we detain a patient against his or her will. Further, the rules regarding detention vary by state and may even mandate release of a patient who is not transferred to an inpatient facility within a set timeframe.

— Sandra M. Schneider, MD, Editor

Introduction

Although rarely discussed as a major mortality factor such as cancer and heart disease, suicide is nonetheless one of the top 10 causes of death in the United States.¹ Further, those with elevated suicidal risk may comprise a significant percentage of individuals presenting to emergency departments; thus, to increase detection, prevention, and treatment of suicidality, emergency departments would appear to be an ideal location for enhanced assessment of dangerousness to self.² Recognizing this, The Joint Commission created National Patient Safety Goal (NPSG) 15.01.01 in 2010, which requires “behavioral health care organizations, psychiatric hospitals, and general hospitals treating individuals for emotional or behavioral disorders to identify patients at risk for suicide.”³

This NPSG has raised controversy in numerous EDs for several reasons. First, it is unknown how many patients visit an ED as opposed to their primary care clinic before suicide.⁴ Second, there are legitimate concerns among emergency clinicians that the detention of a subset of patients for additional mental health

Executive Summary

- Recently The Joint Commission created a new standard, which calls for the identification of ED patients who are suicidal. This is based, in part, on the fact that a significant proportion of patients who die by suicide are seen in the ED in the months prior to their suicide. However, many of these patients are seen for non-mental health reasons.
- When a patient presents with suicidal ideation, attention to the patient's safety, as well as to their acquaintances and the ED staff, is paramount. Patients should be searched for weapons and placed in a prepared room without potential weapons.
- The initial evaluation should attempt to identify high-risk factors, such as substance abuse, feelings of hopelessness or purposelessness, and a plan.
- Use of a contract to prevent suicide has not been 100% effective. It is suggested that discharged patients should develop a "safe plan" of action should they have suicide ideation in the future.

evaluations, solely due to the results of universal screening, could potentially escalate overcrowding and delays in emergency departments. Finally, there has been no research showing reduced mortality from universal screening in the ED.⁵

The fact that a majority of patients visit a primary care provider before suicide has been well documented. A meta-analysis of 40 such studies concluded that the vast majority of patients had visited a primary care provider within one year of suicide, and 20% had contact with mental health services in the month before their suicide.⁶ Although practice patterns for suicide evaluation can vary widely in U.S. emergency departments, there is reason to believe that the ED has been an important identification point for patients, albeit with varying levels of sensitivity and specificity.⁷ One study indicated that 39% of patients who died by suicide in Leeds, England, from 1994-1999 had presented to an emergency department within 12 months.⁸ Another study by Kemball and colleagues indicated that only 25% of patients who disclosed suicidal ideation when asked had any mention of this noted on the chart, and only 10% were admitted or transferred to psychiatric services after their ED visit.⁹

Rationale for Knowledge of Suicide Assessment by Emergency Clinicians

Although the ED may have a pivotal role for patients with thoughts

of self-harm, training for emergency clinicians in this area has been scant. In part, this is because specialized training on behavioral crises is a relatively new concept; indeed, training in any behavioral emergencies was almost non-existent before the 19th century.¹⁰ Prior to this, individuals with mental illness, when treated by physicians at all, were typically cared for by general practitioners with little expertise in psychiatry.

Unfortunately, the situation has not improved much in modern times, with most emergency physicians also receiving little or no formal training in behavioral emergencies, despite the increasing numbers of psychiatric patients who present to a typical general emergency department.¹¹⁻¹³ This suggests an imbalance between patient demand and expert availability for treatment, and also suggests a possible explanation for the low concordance rates between emergency medicine clinicians and psychiatrists about the appropriate disposition for patients with behavioral emergencies.¹⁴

Despite the lack of formal residency training in suicide assessment, emergency clinicians now should add these skills for at least two reasons. First, despite the increasing number of psychiatric patients, not all EDs have consistent access to mental health specialists. In one study by Baraff et al (2006), 23% of emergency department directors stated that suicidal patients in their ED were occasionally discharged without an evaluation by a mental health

professional, and 8.5% reported that this was done 10% of the time or more.⁷ Second, even if emergency clinicians are fortunate enough to have 24-hour access to mental health professionals, many of these are not physicians, and emergency clinicians must be able to judge the soundness of consultant recommendations before admitting or discharging a patient in their care.

The following manuscript, therefore, written in cooperation with experts from the American Association for Emergency Psychiatry, will present the fundamentals of suicide assessment. The focus of this review is for the benefit of the emergency clinician. No formal training in suicide or mental health assessment is assumed.

Initial Approach to the Patient with Suicidal Ideation

Proper planning for suicidal patients in the ED starts prior to any patient arrival. The ED has been termed the "de facto option for initial identification and treatment of suicidal patients," and so it should have a system in place to identify these patients early, preferably at triage.¹⁵ Once patients are identified as being at risk for self-harm, they should not be returned to the waiting room unsupervised; instead, they should be placed in a specially prepared patient room within the emergency department. This space should be free of the normal array of sharp

medically oriented tools found in the average ED room, and should allow for easy visualization of patients at all times. Ideally, this room should also be readied in advance so as to save patients the humiliation of watching staff “prepare their area” by removing all objects.

Clinicians or safety staff should ask patients about any weapons or medications that they may have on their person. Even though the suicidal patient is in a more controlled environment, there still may be significant risk for the patient who is firmly set on dying; unfortunately, suicides completed by patients within the ED are far too common.¹⁶ If the patient does have medications from home, these should be secured prior to leaving the patient alone in the room.

Next, the emergency clinician should make a rapid assessment of provider safety. Although many suicidal patients are withdrawn or quiet, patients who are suffering from hallucinations, mania, alcohol intoxication, or drug intoxication may be agitated and aggressive. Patients who are agitated and who have a history of violence may become dangerous; in fact, a history of violence is the best predictor for future violence. Staff should be cautious with any such patients, particularly if they have ever been violent in health care settings.¹⁷ If the patient has not already been through a screening process, providers should rapidly ascertain if the patient brought any weapons (or objects that could be used as weapons) to the emergency department, and ensure any that are discovered are removed. Some facilities routinely ask such patients to pass through a metal detector or wand them for metallic objects.

During the initial screening, patients should be asked about thoughts of harming others, which can often accompany suicidal ideation. If a patient is determined to be a danger to others as well as self, the patient should be isolated from individuals to whom they might cause harm.

After ensuring provider safety, emergency clinicians next should

perform a rapid but thorough medical assessment. If the patient has already attempted to end his or her life, resuscitative measures take priority. The ABCs (airway, breathing, circulation) should be managed first, bleeding controlled, and life-threatening toxidromes treated immediately. Sometimes, a patient wishing to end his or her life may not be forthcoming about an ingestion. Careful attention will need to be paid if overdose is suspected.

Unfortunately, a tension often exists between emergency clinicians who wish to expedite these steps of triage, medical assessment, and resuscitative measures and patients who may be frightened by the large numbers of ED staff who are suddenly assessing them. If the patient suddenly decides to leave, the emergency clinician may be called upon to perform a quick assessment of the patient’s capacity for decision-making and whether some other form of hold is required (see “Discharging the Patient with Suicidal Ideation”). In general, although slightly more time-consuming, it is best to use finesse instead of force in these situations: Introduce the clinicians by name, reassure the patients that they are safe and no harm will come to them, explain why additional staff is needed, and let the patient know what will be happening.

Restraints and Involuntary Holds for Patients with Suicidal Ideation

Most suicidal patients who present to the ED have come voluntarily and will not need to be restrained if they try to leave. In most cases, these patients will stay with some reassurance about the process. Occasionally, patients who are violent toward others, imminently violent toward themselves, or are unable to make decisions may require some form of restraint. Most ED clinicians are quite familiar with the concept of restraining patients, and the benefits of doing so often might seem obvious.¹⁸ However, many ED clinicians

may not be so familiar with the controversy surrounding the use of restraints.¹⁸⁻²⁰

The use of restraints has been discouraged by most medical and professional societies. Although the complication rate of restraints in one prospective study was low, restraint-related injuries were the seventh most frequently reported event to The Joint Commission.²⁰⁻²¹ In addition, although there are no studies that support the use of restraints, there are by now a number of studies documenting the harm of this practice.²²⁻²⁵ Finally, patients who have had a history of traumatic assault, especially rape, have noted that being restrained caused feelings of re-victimization.²⁶ As a result, many nursing organizations, most psychiatry organizations, and a recent expert consensus panel from the American Association for Emergency Psychiatry have called for limiting the use of restraints to exceptional circumstances, and only as a last resort.²⁷⁻²⁹

If restraints are used, they are acceptable only in an emergency situation in which there is an immediate danger to self or others. Emergency clinicians have been successfully sued for restraining patients when only a minor probability of harm exists and for not documenting that less restrictive interventions were tried first.³⁰ Restraints cannot be used on patients who are merely loud or disruptive, who refuse medication, or simply to aid in undressing patients who refuse to get unclothed.^{18,31} Patients who are restrained must be observed according to applicable regulations and hospital protocol, with frequent reassessments.

Emergency clinicians may also sometimes be asked to place suicidal patients on an involuntary mental health hold. Although state statutes for mental health holds vary, most courts have held that adults who are not under conservatorship have a fundamental right to refuse even needed treatment, as long as they do not pose a serious risk of harm to themselves or others in the near future.³¹ If a patient is placed on an

Table 1: Warning Signs of Imminent Suicide³⁸

IS PATH WARM?

- Ideation
- Substance abuse
- Purposelessness
- Anxiety
- Trapped
- Hopelessness
- Withdrawal
- Anger
- Recklessness
- Mood changes
- ? You must ask

involuntary hold, the clinician should know and follow all local and state regulations regarding this practice. Although emergency physicians have occasionally been sued for involuntary detention of patients, this is rarely successful unless the clinician fails to follow appropriate laws or does not document the case well.³⁰ In most cases, courts have found that safety, related to the imminent danger the patient posed, outweighed the liberty interest set forth in the Constitution.

Initial Psychiatric Assessment

Although it has been fairly consistent that approximately 11.3 United States citizens per 100,000 will die by suicide, it has proven extremely difficult to accurately predict which individuals will do so.³² For every suicide death, the United States Centers for Disease Control and Prevention reports that approximately 11 more suicide attempts have occurred, although some sources cite much higher numbers in the range of 10-20 attempts per suicide death.^{1,33} In part, the complexity of suicide prediction is increased by the necessity of assessing a large number of potential risk factors (suicide risk assessment), as well as the ambiguity of compiling these data into a general opinion about the degree of suicidal risk (suicide risk formulation). For mental health clinicians, the exact art of suicide risk assessment and formulation is honed over the course of training and

experience in the specialty. As noted above, most emergency medicine physicians do not have this training and experience as part of their residency. Even if they have been able to acquire such a skill set, there is rarely enough time for an attending to conduct a thorough suicide assessment in a busy ED. Consequently, emergency clinicians should mostly err on the side of caution by obtaining expert consultation for all but the lowest risk patients (see “Who Is a Low-risk Patient?”).

Although the exact method of establishing suicide risk may vary from provider to provider, most mental health clinicians believe this is best determined by performing a structured evaluation of three domains: assessment of current suicidal thoughts, assessment of risk factors, and assessment of protective factors.³⁴ These three domains are then combined, using professional judgment, into a final formulation of risk.

Of note, several major organizations have sponsored a risk-assessment tool that takes the clinician through this process and aids in the formulation and disposition. The tool is called the Suicide Assessment Five-step Evaluation and Triage (“SAFE-T”). It was specifically designed for mental health professionals, but may be helpful to have as a resource. This pocket-card resource reminds the busy clinician of the major risks and protective factors and questions to use in the suicide inquiry.³⁵ (*For more information, see reference 35.*)

New standards by The Joint Commission recommend the identification of patients at risk for suicide among the patients who seek care in the ED. While many patients who later attempt suicide are seen in the ED prior to their act, many of them are not seen for a mental health issue.

The first step after identifying a patient at risk for self-harm is to place the patient in a “safe” room away from potential weapons and rapidly screen for safety concerns for the patient, staff, and other individuals. Restraints are used only when necessary and then documentation should be adequate.

Patients should be asked about feelings of hopelessness, suicidality, past suicide attempts, substance abuse, and whether they have a plan for completing their suicide.

Contracts with patients regarding future suicide attempts have not been 100% effective. Instead, patients who are discharged should have a written “safe” plan, which outlines what they can do if they start to feel suicidal.

Notably, not all mental health professionals agree with this model. Some argue that clinical assessment, focusing solely on the treatment needs of patients, is more important than perceived risk formulations.³⁶ Some providers also incorporate more information than that contained in a traditional risk assessment. Depending on the mental health provider, this assessment may involve various unique factors, such as intuition, experience, and familiarity with the patient.³⁷ In a system with mental health clinicians who rely solely on a clinical assessment for evaluation, emergency clinicians may find it difficult to accurately predict what their mental health colleagues would have done for a particular patient. Thus, more rather than less expert consultation may be required, and emergency clinicians should defer to the practice standard at their institution.

If patients are evaluated with a traditional structured assessment, this typically begins by asking about

Table 2: Important Selected Risk Factors for Suicide

- Presence or absence of a plan
- Lethality of the plan
- Presence of a weapon at home
- Psychosocial stressors
- Previous attempts and their lethality
- Presence of hopelessness
- Presence of psychosis
- Family history of suicide or mental illness
- Physical illness
- Demographics: older than the age of 65 years, males, Caucasian
- Current psychiatric diagnosis
- Previous psychiatric history: depression or a personality disorder

Table 3: Important Selected Protective Factors

- Religious beliefs around suicide
- Life satisfaction
- Good social/family support
- Ability to cope with stress
- Responsibility to children or pets
- Future planning/goals

current suicidal thoughts. Effective, targeted questions to ask include “Have you ever felt that life was not worth living?” or “Have things reached the point where you’ve thought of harming yourself?”³⁸ If the patient answers yes, clinicians should inquire about a plan and ask about the availability of weapons. Subsequent questions to ask include “Have you made a specific plan to harm or kill yourself? What does the plan include?”³⁸

Patients may have suicidal thoughts that involve a plan, but do not include any real intent to act on the plan. It is important to understand the patient’s intent to act, such as by asking “I hear that you wish you were not alive and can imagine overdosing on pills; how likely are you to do this?” Clinicians should ask about precipitating factors by asking “What led up to these thoughts? What happened afterward?” It is also very important to ask about previous self-harm behaviors and attempts. The clinician should specifically focus on lethality of previous suicide attempts, which have been found to be a strong indicator of future lethality.³⁸

Next, clinicians should evaluate risk factors. These are typically divided into chronic (also called baseline or non-modifiable) and acute (or potentially modifiable) factors. This method of appraisal has been likened to the assessment of myocardial infarction.³⁹ Not every elderly male with a past medical history of diabetes and hypertension will have a myocardial infarction, for instance, but an individual male with this past medical history (baseline risk factors) who presents to the ED with chest pain and shortness of breath (acute signs) should be carefully assessed, even if his symptoms initially are somewhat atypical.

Perhaps by training, emergency clinicians often focus on acute factors instead of chronic or baseline risk factors.⁴⁰ Along these lines, the American Association for Suicidology has put a high priority on recognizing particularly concerning acute factors, termed warning signs. Warning signs have been defined as a “detectable observation that is associated with, hence suggests, heightened risk for suicide in the near-time (i.e., within hours or days).”⁴¹ Patients displaying any of these warning signs

in Table 1 should be considered to be at significant risk.

Hopelessness is a particularly concerning sign, typically assessed by the question “Do you think that things are ever going to get better?”³⁸

The complete list of risk factors for suicide includes numerous factors, with the last American Psychiatric Association guideline on suicide risk assessment listing several dozen. Many of the important risk factors for suicide that are often ascertained during a standard ED history and physical examination are listed in Table 2.

In psychological studies of patients who have died by suicide (the so-called “psychological autopsy”), a vast majority met criteria for a mental disorder.⁴² Studies have shown that approximately 90% of suicide completers have a psychiatric diagnosis at the time death.⁴³⁻⁴⁴ In particular, a psychiatric diagnosis of depression is an important risk factor.⁴⁵ Mood disorders,⁴⁶ substance-use disorders,⁴⁷⁻⁴⁹ psychotic disorders,^{46,48} and borderline personality disorder⁴⁹⁻⁵⁰ all elevate risk. Anxiety disorders also increase risk of suicide, particularly if occurring with depression.⁵¹⁻⁵² Incidentally, one underappreciated risk factor may simply be seeking treatment at an emergency department. Crandall et al noted that the suicide rate for patients seen in the emergency department for suicidal ideation, self-harm, or overdose were 5.8 times as likely to die by suicide as other patients.⁵³

One other important and frequently noted acute risk factor in the ED is substance abuse. Most ED clinicians are quite familiar with alcohol-intoxicated patients who present with thoughts of self-harm. Complicating their assessment, it is often difficult to obtain a good history from intoxicated patients. Consequently, emergency clinicians should wait until the patient is sober enough to provide a good history before assessing suicidal intent. The exact definition of “sober enough” is frequently a matter of contention between psychiatry and emergency clinicians. However, the American

Table 4: The Modified SAD PERSONS Score

Factors	Points
S Sex: male	1
A Age: < 19 or > 45 years	1
D Depression or hopelessness	2
P Previous attempts or psychiatric care	1
E Excessive alcohol or drug use	1
R Rational thinking loss	2
S Separated/divorced/widowed	1
O Organized or serious attempt	2
N No social supports	1
S Stated future intent	2

Table 5: The Manchester Self-Harm Rule

- Any history of self-harm
- Previous psychiatric treatment
- Benzodiazepine use in attempt
- Any current psychiatric treatment

College of Emergency Physicians' clinical policy on assessment of psychiatric patients in the ED recommends that "the patient's cognitive abilities, rather than a specific alcohol level, should be the basis on which clinicians begin the psychiatric assessment."⁵⁴

Alcohol use elevates the risk of self-harm, particularly when the patient's thinking process is impaired, or if the patient becomes more impulsive while drinking. However, studies have indicated that alcohol use also elevates the risk of self-harm even when patients are not intoxicated.⁴ In one study of 298 patients with alcohol-use disorder, 19% had a history of at least one suicide attempt.⁵⁵

As the patient sobers, thoughts of self-harm often abate. However, even though these patients may be sober and completely denying suicidal thoughts, it is important to refer patients for substance-abuse treatment and counseling upon discharge, especially if the clinician thinks that the patient is likely to resume drinking.

Many patients with thoughts of self-harm may be poor historians, even if their thinking process is not impaired by alcohol or other drugs.

As such, collateral information from family, friends, outpatient providers, and/or past medical records should be used, and are considered an important part of suicide risk assessment. Close family members or other loved ones may provide a distinctly different history than that provided by the individuals themselves, especially if a patient still wishes to die by suicide. The suicidal patient may minimize past treatment, attempts, and current symptoms. Emergency clinicians, therefore, should use all available sources of information, as well as asking a patient for the phone numbers of close friends or relatives, before discharging a patient with suicidal ideation. Reluctance of a patient to give out contact information for any family or friends should be of concern. (See "Discharging the Patient with Suicidal Ideation.")

Some factors may decrease the risk of suicide.⁵⁶⁻⁵⁷ As the third step of the suicidality evaluation, clinicians should assess the presence of protective factors, some of which are noted in Table 3. There should be caution around the idea that being "religious" is, in and of itself, a protective factor. In fact, it is the belief system around suicide that is the important aspect. Some beliefs include hell or

purgatory for those who die by suicide, while others believe that God is understanding and forgiving about the act. This second interpretation, as might be imagined, does not deter suicide, while the former can be a compelling mitigating factor preventing suicide.

After assessment of the factors in Tables 2 and 3, the formulation of risk is undertaken by weighing the balance of factors. Risk and protective factors should not be considered one-to-one, or "balancing each other out." Instead, the clinician will need to weigh the importance of each in making a safety formulation.⁵⁶⁻⁵⁷ Based on the perceived level of risk, the clinician will also need to weigh several factors when determining whether to admit the patient, especially if the admission is involuntary. If the patient is deemed to be imminently dangerous to self, admission or further observation is clearly necessary. It is much more of a difficult situation when the patient has vague or moderate suicidal thoughts, a plan but no current intent, and mixed risk and protective factors. Specialists in mental health should be brought in for these cases to assist in making the final decision on disposition.

Other factors to weigh in determining need for hospitalization include judging whether the inpatient stay would be beneficial in reducing the patient's risk of suicide (especially if the patient is chronically suicidal), or whether it would be more harmful in terms of such things as lost pay at work, expensive hospital bills, social stigma, and the coercion involved in involuntary hospitalization.

Use of Screening Tools

Given the large numbers of potential risk factors and the observation that some variables (such as hopelessness and ideation with specific lethal means) are weighted more heavily in risk assessment, much research effort has attempted to develop simplified scoring systems for suicide prediction. In general, these efforts have failed to produce a scoring instrument that is perfectly predictive of

imminent suicide. Most current scoring systems indicate heightened risk of suicide, but are not sensitive enough to detect which particular individual high-risk patients will attempt suicide.⁵⁸

Some ED researchers have taken the opposite approach, namely the development of scoring systems that identify patients at lowest risk of suicide (see “Who Is a Low-risk Patient?”). Although this approach has generally been more successful, existing scoring systems have not been developed for this purpose. Although multiple screening tools exist, two current systems, the modified SAD PERSONS score (see *Table 4*) and the Manchester Self-Harm Rule (see *Table 5*), have been proposed specifically for use in the emergency department. The modified SAD PERSONS score incorporates 10 criteria for assessment of potential suicidal patients with differential weighting for each factor. Both the modified SAD PERSONS and the original SAD PERSONS scale on which it is based have shown poor predictive value for future suicide attempts.⁵⁹

In a 1988 article, however, Hockberger and Rothstein showed that patients with suicidal ideation who had a score of 6 or more were consistently hospitalized by the UCLA Department of Psychiatry.⁶⁰ This rule, although limited by the practice of a single center, correctly categorized patients with a sensitivity of 94% and a specificity of 71%. This may indicate that the rule performs better on categorizing low-risk patients for ED discharge than it does for predicting suicide in higher-risk patients. However, it remains to be seen through further research if this scale can be generalized to other types of patients or institutions.

The Manchester Self-Harm Rule, comprised of four questions, was designed to determine the risk of suicide within six months in patients presenting after self-harm.⁶¹ In the validation cohort, the rule performed impressively well, with a sensitivity of 94% and a specificity of 25%. However, like the modified

SAD PERSONS score, the rule may have limited generalizability. In the Manchester derivation cohort, benzodiazepine overdose was a significant predictor of eventual suicide. This is not true of other localities, such as the United States, where firearms are the most common method of suicide. Further, in cities like San Diego, only a small number of individuals who have died by suicide test positive for benzodiazepines at autopsy.⁶² In addition, the Manchester Self-Harm Rule does not include other important risk factors such as those in *Table 1* or most in *Table 2*.

At the current time, clinical risk scores such as these cannot predict suicide in an individual, and a particular score should not be used to justify admission to the hospital.⁵⁸ There are several groups investigating better assessment tools. There is also some early work on biomarkers.⁶³

Who Is a Low-risk Patient?

If the definition of a high-risk patient depends on the formulation of risk after careful assessment of a number of variables, which factors predict a low-risk patient? In other words, are there any patients whom emergency clinicians can discharge without a time-consuming wait for a mental health consultation?

Although the exact answer to this is controversial, with some clinicians advocating for a full risk assessment in all mental-health patients, some guidelines for the discharge of extremely low-risk patients can be proposed for the emergency department. In general, an extremely low-risk patient has either no desire or very vague desire for self-harm, does not have a lethal plan for self-harm, has no weapons at home, is not hopeless, is optimistic and making future plans, has not made previous suicide attempts, and is able to engage with the interviewer. Conversely, patients who attempt to conceal information from the interviewer or who have impaired thinking because of psychosis or substance

use should be presumed to be at higher risk. Of course, consultation should be obtained for all patients in whom the ED clinician cannot effectively establish that the risk is very low, or if the clinician feels any degree of uncertainty.

Who Gets Hospitalized?

The exact method of combining variables obtained in a suicide risk assessment into a suicide risk formulation is complex, and can vary by practitioner (see “Initial Psychiatric Assessment”). In general, patients hospitalized for suicidality are the opposite of low-risk patients, and are individuals who are at near-term risk for self-harm. This of course leaves a large continuum of patients in the middle. These patients may have some risk factors or may have a chronic waxing and waning level of suicidal ideation. Mental health consultants are particularly useful for these patients, and may be able to offer many types of support other than hospitalization, such as brief interventions, crisis housing, acute diversion units, or expedited mental health appointments.⁵⁷

Discharging the Patient with Suicidal Ideation

Discharge of the patient with suicidal ideation can sometimes be ethically challenging. For instance, when is it appropriate to allow a patient with thoughts of self-harm to make decisions about his or her own care? When can these patients be trusted to leave against medical advice without further structured care for their thoughts of self-harm? Should suicidal patients be restrained or placed on involuntary holds to prevent their leaving the emergency department?

In general, when deciding whether a suicidal patient is able to leave the ED, the same standards as for other patients should be applied. Although competency is a legal determination, capacity is a clinical concept that refers to the patient’s ability to make decisions about their medical care. In order to be considered capable, patients must have a factual

understanding of the nature of the proposed treatment, the risks of that treatment, and alternatives to treatment.

Informed refusal implies that the patient understands the consequences of refusing that treatment, and is able to rationally weigh the risks and benefits of rejecting care. Unless there is a clear reason to believe that the patient's decision-making capacity is impaired in some way, patients should be allowed to make choices about their situation. Simply put, is the patient capable of understanding the benefits of, and the risks of refusing, the proposed treatment? If so, the patient has capacity to refuse, just as any non-psychiatric patient has the ability to decline even what might be considered necessary treatment.³¹

Patients who are deemed to have decisional capacity may not be restrained or placed on involuntary holds for refusing treatment unless they are determined to be at imminent risk of harming themselves or others (see "Restraints and Involuntary Holds for Patients with Suicidal Ideation").

There is sometimes a temptation upon discharge to "contract a patient for safety," i.e., have patients sign a written contract stating that they will not harm themselves. In general, contracts for safety are neither safe nor good contracts. Many patients have attempted suicide after signing safety contracts, and such contracts have been dismissed by both courts and legal analysts.⁶⁴

Instead, providers should help a patient formulate a good safety plan prior to discharge. Safety plans should be written by the patient and attempt to identify coping strategies that the patient can use when starting to feel unsafe. This plan could include listening to music, watching television, taking a walk, calling a family member or friend, or calling a support line. The American Association of Suicidology recommends specific, clear discharge information to include education about suicide, including warning signs, increased risks of suicide following

discharge, the need for medication and taking this as directed, the need for stopping intoxicating substances, and the risks of having weapons available.⁶⁵ This information should be provided in written form if possible. Phone numbers to support lines or suicide hotlines should be given with discharge instructions as further support. The patient should also be told to return to the ED with return or worsening of symptoms, especially if there is a safety concern.

Finally, the individual should be assessed for the potential of harm to others. If the patient is dangerous to a particular individual, then clinicians have a duty to warn the person or persons involved. As with other laws, various states have interpreted this mandate differently, and the clinician should have an understanding of local statutes.⁶⁶

Conclusions

Given the increasing numbers of mental health patients coming to emergency departments, and the common lack of access to mental health professionals, emergency clinicians need to understand the basics of suicide assessment. In the ED, identification of patients at risk for suicide should begin early, preferentially at triage. This requires institutional support so that once identified, patients can be promptly diverted into "safe" rooms that do not contain objects that could be used as weapons, nor access to medications nor poisons.

Providers should rapidly make an assessment of safety as part of, or before commencing, medical evaluation. It should be recognized that most suicidal patients are not imminently dangerous, do not require restraint or locked seclusion, and are capable of making decisions about their own treatment.

Once medical evaluation is complete, clinicians should perform a basic psychiatric assessment. This assessment, using collateral information from family and others if possible, should include the presence of suicidal ideation, the nature of any plans for suicide, the lethality of that

plan, level of intent to act on the plan, and delineation of precipitating factors that led to suicidality. In general, emergency clinicians should err on the side of caution by obtaining mental health consultation for all patients who are not definitively low risk.

Discharge of patients with suicidal ideation from the ED should involve a good patient safety plan. Contracts for safety may not be appropriate, but emergency clinicians should involve family or friends in the discharge process to further support the patient and the safety/discharge plan. Patients should always feel welcome to return to the ED as necessary.

References

1. Centers for Disease Control and Prevention (CDC). Web-based Injury Statistics Query and Reporting System (WISQARS). National Center for Injury Prevention and Control, CDC (producer). Available at: http://www.cdc.gov/injury/wisqars/pdf/10LCID_All_Deaths_By_Age_Group_2010-a.pdf. Accessed December 19, 2013.
2. Mitchell AM, et al. Suicide Assessment in Hospital Emergency Departments: Implications for Patient Satisfaction and Compliance. *Top Emerg Med* 2005;27(4):302-312.
3. The Joint Commission. A follow-up report on preventing suicide: Focus on medical-surgical units and the emergency department. *Sentinel Event Alert* 2010;46:1-4.
4. Ronquillo L, Minassian A, Vilke GM, Wilson MP. Literature-based recommendations for suicide assessment in the emergency department: A review. *J Emerg Med* 2012;43(5):836-842.
5. Agency for Healthcare Research and Quality. Screening for suiciderisk: a systematic evidence review for the US Preventive Services Task Force (2004). Available at: <http://www.ahrq.gov/downloads/pub/prevent/pdfser/suicid-ser.pdf>. Accessed January 14, 2011.
6. Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: A review of the evidence. *Am J Psychiatry* 2002;159:909-916.
7. Baraff LJ, Janowicz N, Asarnow JR. Survey of California emergency departments about practices for management of suicidal patients and resources available for their care. *Ann Emerg Med* 2006;48:452-458.
8. Gairin I, House A, Owens D. Attendance at the accident and emergency department in the year before suicide:

- Retrospective study. *Br J Psychiatry* 2003;183:28-33.
9. Kemball RS, Gasgarth R, Johnson B, Patil M, Houry D. Unrecognized suicidal ideation in ED patients: Are we missing an opportunity? *Am J Emerg Med* 2008;26:701-705.
 10. Porter R. The greatest benefit to mankind. A medical history of humanity from antiquity to the present. London: Harper-Collins; 1997:831.
 11. Weissberg M. The meagerness of physicians' training in emergency psychiatric intervention. *Acad Med* 1990;65(12):747-750.
 12. Larkin GL, Classen CA, Emond JA, Pelletier AJ, Camargo CA. Trends in US Emergency Department Visits for Mental Health Conditions, 1992 to 2001. *Psychiatr Serv* 2005;56(6):671-677.
 13. Schmitz WM, Allen MH, Feldman BN, et al. Preventing suicide through improved training in suicide risk assessment and care: An American Association of Suicidology task force report addressing serious gaps in US mental health training. *Suicide Life Threat Behav* 2012;42(3):292-304.
 14. Douglass AM, Luo J, Baraff LJ. Emergency medicine and psychiatry agreement on diagnosis and disposition of emergency department patients with behavioral emergencies. *Acad Emerg Med* 2011;18:368-373.
 15. D'Onofrio G, Jauch E, Jagoda A, Allen MH, Anglin D, Barsan WG et al. NIH Roundtable on opportunities to advance research on neurologic and psychiatric emergencies. *Ann Emerg Med* 2010;56:551-564.
 16. Mills, PD, et al. Suicide attempts and completions in the emergency department in Veterans Affairs hospitals. *Emerg Med J* 2012;29(5):399-403.
 17. Elbogen EB, Johnson SC. The intricate link between violence and mental disorder. *Arch Gen Psychiatry* 2009;66(2):152-161.
 18. Wilson MP, Sloane C. Chemical restraints, physical restraints, and other demonstrations of force. In: Jesus J, Rosen P, Adams J, Derse A, Wolfe R, Grossman S, editors. Ethical problems in emergency medicine: A discussion-based review. Oxford: Wiley-Blackwell; 2012:139-148.
 19. Stewart D, Bowers L, Simpson A, Ryan C, Tziggili M. Manual restraint of adult psychiatric inpatients: A literature review. *Journal of Psychiatric Mental Health Nursing* 2009;16(8):749-757.
 20. Holloman GH, Zeller SL. Overview of Project BETA: Best Practices in Evaluation and Treatment of Agitation. *WJEM* 2012;13(1):1-2.
 21. Zun LS. A prospective study of the complication rate of use of patient restraint in the emergency department. *J Emerg Med* 2003;24(2):119-124.
 22. Eadie KJ. Aggression: Reducing risk in the management of aggressive patients. SAFE MD: Practical applications and approaches to safe psychiatric practice. Jayaram G, Herzog A, editors. 2009. Accessed at psych.org on June 24, 2011.
 23. Frueh BC, Knapp RG, Cusack KJ, et al. Patients' reports of traumatic or harmful experiences within the psychiatric setting. *Psychiatr Serv* 2005;56:1123-1133.
 24. Cusack KJ, Frueh BC, Hiers T, Suffoletta-Maierle S, Bennett S. Trauma within the psychiatric setting: A preliminary empirical report. *Administration and Policy in Mental Health* 2003;30(5):453-460.
 25. Robins CS, Sauvageot JA, Suffoletta-Maierle S, Frueh BC. Consumer's perceptions of negative experiences and "Sanctuary Harm" in psychiatric settings. *Psychiatr Serv* 2005;56:1134-1138.
 26. Smith SB. Restraints: retraumatization for rape victims? *J Psychosoc Nurs Ment Health Serv* 1995;33:23-28.
 27. American Psychiatric Nurse's Association. Position statement on the use of seclusion and restraint. 2007. Accessed at www.apna.org on June 24, 2011.
 28. American Academy of Child and Adolescent Psychiatry (2002), Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. *J Am Acad Child Adolesc Psychiatry* (Supplement) 41:4S-25S.
 29. Knox DK, Holloman GH. Use and avoidance of seclusion and restraint: Consensus statement of the American Association for Emergency Psychiatry Project BETA seclusion and restraint workgroup. *West J Emerg Med* 2012;13(1):35-40.
 30. Stefan S. Legal issues in the care of psychiatric patients. In: Zun LS, Chepenik LG, Mallory MNS, editors. Behavioral Emergencies for the Emergency Physician. Cambridge: Cambridge University Press: 362-372.
 31. Stefan S. Assessing capacity, involuntary assessment, and leaving against medical advice. In: Zun LS, Chepenik LG, Mallory MNS, editors. *Behavioral Emergencies for the Emergency Physician*. Cambridge: Cambridge University Press: 324-334.
 32. Centers for Disease Control and Prevention (CDC). Web-based Injury Statistics Query and Reporting System (WISQARS) (2010). National Center for Injury Prevention and Control, CDC (producer). Available at: www.cdc.gov/injury/wisqars/index.html. Accessed March 13, 2011.
 33. Anatai-Otong D. Psychiatric Emergencies: How to accurately assess and manage the patient in crisis. Wisconsin: PESI, LLC.; 2009.
 34. Menon V. Suicide risk assessment and formulation: An update. *Asian J Psychiatry* 2013;6:430-435.
 35. SAFE-T (suicide risk assessment). Found at: http://www.integration.samhsa.gov/images/res/SAFE_T.pdf.
 36. Ryan C, Nielssen O, Paton M, et al. Clinical decisions in psychiatry should not be based on risk assessment. *Australas Psychiatry* 2010;18(5):398-403.
 37. Bhugra D, Malliaris Y, Gupta S. How shrinks think: Decision making in psychiatry. *Australasian Psychiatry* 2010;18(5):391-393.
 38. Jacobs DG, Baldessarini RJ, Conwell Y, et al. Practice guideline for the assessment and treatment of patients with suicidal behaviors. *Am J Psychiatry* 2003;260(11 Suppl):1-60.
 39. Berman AL, Silverman MM. Suicide risk assessment and risk formulation Part II: Suicide risk formulation and the determination of levels of risk. *Suicide Life Threat Behav* 2013; epub ahead of print.
 40. Cooper JB, Lawlor MP, Hiroeh U, Kapur N, Appleby L. Factors that influence emergency department doctors' assessment of suicide risk in deliberate self-harm patients. *Eur J Emerg Med* 2003;10:283-287.
 41. American Association for Suicidology. The origin of the evidence-based consensus-developed IS PATH WARM? Warning signs. 2003. Accessed at http://www.suicidology.org/c/document_library/get_file?folderId=231&name=DLFE-598.pdf on December 9 2013.
 42. Cavanagh JTO, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: A systematic review. *Psychol Med* 2003;33:395-405.
 43. Mann JJ. A current perspective of suicide and attempted suicide. *Ann Intern Med* 2002;136:302-311.
 44. Hirschfeld RM, Russell JM. Assessment and treatment of suicidal patients. *N Engl J Med* 1997;337:910-915.
 45. Dumais A, Lesage AD, Alda M, Rouleau G, Dumon M, Chawky N, et al. Risk factors for suicide completion in major depression: A case-control study of impulsive and aggressive behaviors in men. *Am J Psychiatry* 2005;162:2116-2124.
 46. Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism, and schizophrenia. *Br J Psychiatry* 1998;172:35-37.
 47. Fleischmann A, Bertolote JM, Belfer M, et al. Completed suicide and psychiatric diagnoses in young people: A critical examination of the evidence. *Am J Orthopsychiatry* 2005;75:676-683.
 48. Hor K, Taylor M. Review: suicide and schizophrenia: A systematic review of rates and risk factors. *J Psychopharmacol* 2010;24:81-90.
 49. Goodman M, Roiff T, Oakes AH, Paris J. Suicidal risk and management in borderline personality disorder. *Curr Psychiatry Rep* 2012;14:79-85.
 50. Glenn CR, Bagge CL, Osman A. Unique associations between borderline personality disorder features and suicide ideation and attempts in adolescents. *J Pers Disord* 2013;27(5):604-616.
 51. Thibodeau MA, Welch PG, Sareen J, et al. Anxiety disorders are independently

- associated with suicide ideation and attempts: Propensity score matching in two epidemiological samples. *Depress Anxiety* 2013;30(10):947-954.
52. Batterham PJ, Christensen H, Calear AL. Anxiety symptoms as precursors of major depression and suicidal ideation. *Depress Anxiety* 2013;30(10):908-916.
 53. Crandall C, Fullerton-Gleason L, Aguero R, LaValley J. Subsequent suicide mortality among emergency department patients seen for suicidal behavior. *Acad Emerg Med* 2006;13:435-442.
 54. Lukens TW, Wolf SJ, Edlow JA, Shahabuddin S, Allen MH, Currier GW, et al. Management of the adult psychiatric patient in the emergency department. *Ann Emerg Med* 2006;47:79-99.
 55. Roy A, Lamparski D, DeJong J, Moore V, Linnoila M. Characteristics of alcoholics who attempt suicide. *Am J Psychiatry* 1990;147:761-765.
 56. Gray C. Assessment of the suicidal patient in the emergency department. In: Zun LS, Chepenik LG, Mallory MNS, editors. *Behavioral Emergencies for the Emergency Physician*. Cambridge: Cambridge University Press. pp 60-68.
 57. Dawe IC. Suicide and Homicide. In: Glick RL, Berlin JS, Fishkind AB, Zeller SL, editors. *Emergency Psychiatry: Principles and Practice*. Philadelphia: Lippincott Williams & Wilkins; 2008: 149-159.
 58. Cochrane-Brink KA, Lofchy JS, Sakinofsky I. Clinical rating scales in suicide risk assessment. *Gen Hosp Psychiatry* 2000;22:445-451.
 59. Bolton JM, Spiwak R, Sareen J. Predicting suicide attempts with the SAD PERSONS scale: A longitudinal analysis. *J Clin Psychiatry* 2012;73(6):e735-e741.
 60. Hockberger RS, Rothstein RJ. Assessment of suicide potential by nonpsychiatrists using the SAD PERSONS score. *J Emerg Med* 1988;6:99-107.
 61. Cooper J, Kapur N, Dunning J, Guthrie E, Appleby L, Mackway-Jones K. A clinical tool for assessing risk after self-harm. *Ann Emerg Med* 2006;48:459-466.
 62. Mendelson WB, Rich CL. Sedatives and suicide: The San Diego study. *Acta Psychiatr Scand* 1993;88:337-341.
 63. Le-Niculescu H, Levy DF, Ayalew M, et al. Discovery and validation of blood biomarkers for suicidality. *Mol Psych* 2013;18:1249-1264.
 64. Garvey KA, Penn JV, Campbell AL, Esposito-Smythers C, Spirito A. Contracting for safety with patients: Clinical practice and forensic implications. *J Am Acad Psychiatry Law* 2009;37: 363-370.
 65. Knesper DJ, American Association of Suicidology, & Suicide Prevention Resource Center. (2010) Continuity of care for suicide prevention and research: Suicide attempts and suicide deaths subsequent to discharge from the emergency department or psychiatry inpatient unit. Newton, MA: Education Development Center, Inc.
 66. Hughes DH. Suicide and violence assessment in psychiatry. *Gen Hosp Psychiatry* 1996;18:416-421.
- ## CME Questions
1. Which of the following statements is true?
 - A. A majority of patients visit a physician before suicide.
 - B. About half of the patients visit a physician before suicide.
 - C. Less than half of the patients visit a physician before suicide.
 - D. Very few patients visit a physician before suicide.
 2. Which of the following statements is most true?
 - A. Proper assessment of a suicidal patient often takes intensive staff resources so that it can be done quickly.
 - B. Proper planning for a suicidal patient should start before the patient even arrives.
 - C. Suicidal patients always disclose thoughts of self-harm, usually to nursing staff, if they are being seen in the ED.
 - D. Physicians should avoid asking friends or family for information about the patient.
 3. Which of the following statements is most true?
 - A. In general, medications are often required for suicidal patients in the ED.
 - B. In general, restraints are often required for suicidal patients who attempt to leave the ED without completing a full psychiatric assessment.
 - C. In general, involuntary mental health holds are always required for suicidal patients who attempt to leave the ED without completing a full psychiatric assessment.
 - D. A suicidal patient should be mostly sober before completing a psychiatric assessment.
 4. One good way to approach the topic of suicide with patients is by asking which of the following questions?
 - A. "Have you reached the point where you've thought of harming yourself?"
 - B. "Have you thought about suicide?"
 - C. "Have you thought about death?"
 - D. "Why did you come to the ED today?"
 5. Warning signs of imminent suicide include which of the following?
 - A. psychosis
 - B. presence of a weapon at home
 - C. hopelessness
 - D. physical illness
 6. Risk factors for suicide include which of the following?
 - A. age older than 50 years for women, age older than 65 years for men
 - B. responsibility to pets
 - C. life dissatisfaction
 - D. previous serious attempts
 7. Protective factors for suicide include which of the following?
 - A. age older than 50 years for women, age older than 65 years for men
 - B. responsibility to pets
 - C. life dissatisfaction
 - D. previous serious attempts
 8. Which of the following is true?
 - A. Suicide risk assessment and suicide risk formulation are an exact science.
 - B. When performing a traditional risk assessment, clinicians often count the number of risk factors and the number of protective factors. If there are more protective factors than risk factors, the patient is safe for discharge (and vice versa).
 - C. When performing a traditional risk assessment, clinicians often weigh risk factors and protective factors. If protective factors outweigh risk factors or if protective factors outweigh the harm caused by psychiatric hospitalization, the patient will likely be discharged.
 - D. When performing a traditional risk assessment, clinicians often ask questions in four domains.

Emergency Medicine Reports

CME Objectives

Upon completion of this educational activity, participants should be able to:

- recognize specific conditions in patients presenting to the emergency department;
- apply state-of-the-art diagnostic and therapeutic techniques to patients with the particular medical problems discussed in the publication;
- discuss the differential diagnosis of the particular medical problems discussed in the publication;
- explain both the likely and rare complications that may be associated with the particular medical problems discussed in the publication.

9. Which of the following is most true?
- A. Screening tools are recommended to help the clinician remember to ask all of the important questions in suicide assessment.
 - B. Screening tools may be useful in identifying patients at higher or lower risk of suicide, but cannot be used to justify hospital admission.
 - C. Screening tools have been shown to reduce mortality by catching patients at the earliest stage of self-harm thoughts.
 - D. Several selected screening tools have been shown to have excellent predictive value when identifying individual patients who will commit suicide.
10. Which of the following is most true?
- A. Informed refusal involves the following elements: factual understanding of the procedure or treatment; risks of the procedure or treatment; and alternatives to the procedure or treatment.
 - B. Courts often defer to decisions by emergency clinicians regarding competency.
 - C. Suicidal patients may be restrained if they do not wish to comply with needed treatment to prevent self-harm.
 - D. Mental health patients, by virtue of their disease, are often presumed not to have clear decision-making capacity.

CME Instructions

HERE ARE THE STEPS YOU NEED TO TAKE TO EARN CREDIT FOR THIS ACTIVITY:

1. Read and study the activity, using the provided references for further research.
2. Scan the QR code below, or log on to www.cmecity.com to take a post-test; tests can be taken after each issue or collectively at the end of the semester. *First-time users will have to register on the site using the 8-digit subscriber number printed on their mailing label, invoice, or renewal notice.*
3. Pass the online tests with a score of 100%; you will be allowed to answer the questions as many times as needed to achieve a score of 100%.
4. After successfully completing the last test of the semester, your browser will be automatically directed to the activity evaluation form, which you will submit online.
5. **Once the completed evaluation is received, a credit letter will be e-mailed to you instantly.** You will no longer have to wait to receive your credit letter.



To reproduce any part of this newsletter for promotional purposes, please contact:

Stephen Vance

Phone: (800) 688-2421, ext. 5511

Fax: (800) 284-3291

Email: stephen.vance@ahcmedia.com

To obtain information and pricing on group discounts, multiple copies, site-licenses, or electronic distribution please contact:

Tria Kreutzer

Phone: (800) 688-2421, ext. 5482

Fax: (800) 284-3291

Email: tria.kreutzer@ahcmedia.com

Address: AHC Media
One Atlanta Plaza
950 East Paces Ferry Road NE
Suite 2850, Atlanta, GA 30326 USA

To reproduce any part of AHC newsletters for educational purposes, please contact:

The Copyright Clearance Center for permission

Email: info@copyright.com

Website: www.copyright.com

Phone: (978) 750-8400

Fax: (978) 646-8600

Address: Copyright Clearance Center
222 Rosewood Drive, Danvers, MA 01923 USA

Editors

Sandra M. Schneider, MD
Senior Director of Research
Department of Emergency Medicine
North Shore University Hospital
Manhasset, New York

J. Stephan Stapczynski, MD
Chair
Emergency Medicine Department
Maricopa Medical Center
Phoenix, Arizona

Editorial Board

Paul S. Auerbach, MD, MS, FACEP
Professor of Surgery
Division of Emergency Medicine
Department of Surgery
Stanford University School of
Medicine
Stanford, California

**William J. Brady, MD, FACEP,
FAAEM**
Professor and Vice Chair of
Emergency
Medicine, Department of Emergency
Medicine,
University of Virginia School of
Medicine
Charlottesville, Virginia

Michael L. Coates, MD, MS
Professor
Department of Family and
Community Medicine
Wake Forest University School
of Medicine
Winston-Salem, North Carolina

Alasdair K.T. Conn, MD
Chief of Emergency Services
Massachusetts General Hospital
Boston, Massachusetts

Charles L. Emerman, MD
Chairman
Department of Emergency Medicine
MetroHealth Medical Center
Cleveland Clinic Foundation
Cleveland, Ohio

Chad Kessler, MD, MHPE
Deputy Chief of Staff, Durham VAMC
Chairman, VHA Emergency Medicine
Field Advisory Committee
Clinical Associate Professor,
Departments of Emergency Medicine
and Internal Medicine
Duke University School of Medicine
Durham, North Carolina

**Kurt Kleinschmidt, MD, FACEP,
FACMT**
Professor of Surgery/Emergency
Medicine
Director, Section of Toxicology
The University of Texas
Southwestern Medical Center and
Parkland Hospital
Dallas, Texas

Frank LoVecchio, DO, FACEP
Vice-Chair for Research
Medical Director, Samaritan Regional
Poison Control Center
Emergency Medicine Department
Maricopa Medical Center
Phoenix, Arizona

**Larry B. Mellick, MD, MS, FAAP,
FACEP**
Professor, Department of Emergency
Medicine and Pediatrics
Georgia Regents University
Augusta, Georgia

**Paul E. Pepe, MD, MPH, FACEP,
FCCM, MACP**
Professor of Medicine, Surgery,
Pediatrics, Public Health and Chair,
Emergency Medicine
The University of Texas
Southwestern Medical Center and
Parkland Hospital
Dallas, Texas

Charles V. Pollack, MA, MD, FACEP
Chairman, Department of Emergency
Medicine, Pennsylvania Hospital
Associate Professor of Emergency
Medicine
University of Pennsylvania School of
Medicine
Philadelphia, Pennsylvania

Robert Powers, MD, MPH
Professor of Medicine and
Emergency
Medicine
University of Virginia
School of Medicine
Charlottesville, Virginia

David J. Robinson, MD, MS, FACEP
Professor and Vice-Chairman
Department of Emergency Medicine
University of Texas - Health Science
Center at Houston
Houston, Texas

Barry H. Rumack, MD
Professor Emeritus of Pediatrics and
Emergency Medicine
University of Colorado School of
Medicine
Director Emeritus
Rocky Mountain Poison and Drug
Center
Denver, Colorado

John A. Schriver, MD
Chief, Department of Emergency
Services
Rochester General Hospital
Rochester, New York

David Sklar, MD, FACEP
Professor of Emergency Medicine
Associate Dean, Graduate Medical
Education
University of New Mexico School of
Medicine
Albuquerque, New Mexico

Charles E. Stewart, MD, FACEP
Professor of Emergency Medicine,
Director, Oklahoma Disaster Institute
University of Oklahoma, Tulsa

Gregory A. Volturo, MD, FACEP
Chairman, Department of Emergency
Medicine
Professor of Emergency Medicine
and Medicine
University of Massachusetts Medical
School
Worcester, Massachusetts

Steven M. Winograd, MD, FACEP
St. Barnabas Hospital
Clinical Assistant Professor,
Emergency Medicine
New York College of Osteopathic
Medicine
Old Westbury, New York

Allan B. Wolfson, MD, FACEP, FACP
Program Director,
Affiliated Residency in Emergency
Medicine
Professor of Emergency Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania

CME Question Reviewer

Roger Farel, MD
Retired
Newport Beach, CA

© 2014 AHC Media LLC. All rights reserved.

Emergency Medicine Reports™ (ISSN 0746-2506)
is published biweekly by AHC Media LLC, One Atlanta
Plaza, 950 East Paces Ferry Road NE, Suite 2850,
Atlanta, GA 30326. Telephone: (800) 688-2421 or (404)
262-7436.

Editorial Director: Lee Landenberger

Executive Editor: Shelly Morrow Mark

Managing Editor: Leslie Hamlin

GST Registration No.: R128870672

Periodicals Postage Paid at Atlanta, GA 30304 and at
additional mailing offices.

POSTMASTER: Send address
changes to *Emergency Medicine
Reports*, AHC Media LLC, PO Box
550669, Atlanta, GA 30355

Copyright © 2014 by AHC Media LLC, Atlanta, GA. All
rights reserved. Reproduction, distribution, or translation
without express written permission is strictly prohibited.

Back issues: \$31. Missing issues will be fulfilled by
customer service free of charge when contacted within
one month of the missing issue's date.

Multiple copy prices: One to nine additional copies, \$359
each; 10 to 20 additional copies, \$319 each.

Subscriber Information

Customer Service: 1-800-688-2421

Customer Service E-Mail:
customerservice@ahcmedia.com

Editorial E-Mail:
shelly.mark@ahcmedia.com

World Wide Web page:
<http://www.ahcmedia.com>

Subscription Prices

1 year *with* 60 ACEP/65 AMA/39 AAFP
Category 1/Prescribed credits: \$514

1 year *without* credit: \$369
Add \$19.99 for shipping & handling

Resident's rate \$199

Discounts are available for group
subscriptions, multiple copies, site-licenses
or electronic distribution. For pricing
information, call
Tria Kreutzer at 404-262-5482.

All prices U.S. only.
U.S. possessions and Canada, add \$30
plus applicable GST. Other international
orders, add \$30.

Accreditation

AHC Media is accredited by the
Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.

AHC Media designates this enduring
material for a maximum of *65 AMA PRA
Category 1 Credits™*. Each issue has been
designated for a maximum of *2.50 AMA
PRA Category 1 Credits™*. Physicians
should claim only credit commensurate
with the extent of their participation in the
activity.

Approved by the American College of
Emergency Physicians for a maximum of
65.00 hour(s) of ACEP Category I credit.

This enduring material activity, *Emergency
Medicine Reports*, has been reviewed
and is acceptable for up to 39 Prescribed
credits by the American Academy of Family
Physicians. AAFP certification begins
January 1, 2014. Term of approval is for
one year from this date with the option of
yearly renewal.

Each issue is approved for 1.50 Prescribed
credits. Credit may be claimed for one year
from the date of each issue. Physicians
should claim only the credit commensurate
with the extent of their participation in the
activity.

AHC Media has requested that the
American Osteopathic Association (AOA)
approve this program for AOA Category
2-B CME credits. Approval is currently
pending.

This is an educational publication
designed to present scientific information
and opinion to health professionals,
to stimulate thought, and further
investigation. It does not provide
advice regarding medical diagnosis or
treatment for any individual case. It is not
intended for use by the layman. Opinions
expressed are not necessarily those of
this publication. Mention of products or
services does not constitute endorsement.
Clinical, legal, tax, and other comments
are offered for general guidance only;
professional counsel should be sought for
specific situations.

This CME activity is intended for
emergency and family physicians. It is in
effect for 24 months from the date of the
publication.

© 2014 AHC Media LLC. All rights reserved.

AHC Media

Practical Management of the Suicidal Patient in the ED

Warning Signs of Imminent Suicide

- IS PATH WARM?**
- Ideation
 - Substance abuse
 - Purposelessness
 - Anxiety
 - Trapped
 - Hopelessness
 - Withdrawal
 - Anger
 - Recklessness
 - Mood changes
 - ? You must ask

Important Selected Risk Factors for Suicide

- Presence or absence of a plan
- Lethality of the plan
- Presence of a weapon at home
- Psychosocial stressors
- Previous attempts and their lethality
- Presence of hopelessness
- Presence of psychosis
- Family history of suicide or mental illness
- Physical illness
- Demographics: older than the age of 65 years, males, Caucasian
- Current psychiatric diagnosis
- Previous psychiatric history: depression or a personality disorder

Important Selected Protective Factors

- Religious beliefs around suicide
- Life satisfaction
- Good social/family support
- Ability to cope with stress
- Responsibility to children or pets
- Future planning/goals

The Modified SAD PERSONS Score

Factors	Points
S Sex: male	1
A Age: < 19 or > 45 years	1
D Depression or hopelessness	2
P Previous attempts or psychiatric care	1
E Excessive alcohol or drug use	1
R Rational thinking loss	2
S Separated/divorced/widowed	1
O Organized or serious attempt	2
N No social supports	1
S Stated future intent	2

The Manchester Self-Harm Rule

- Any history of self-harm
- Previous psychiatric treatment
- Benzodiazepine use in attempt
- Any current psychiatric treatment

Supplement to *Emergency Medicine Reports*, January 5, 2014: “Practical Management of the Suicidal Patient in the Emergency Department.” Authors: **Michael P. Wilson, MD, PhD, FAAEM**, Attending Physician, University of California–San Diego Department of Emergency Medicine, Director, Department of Emergency Medicine Behavioral Emergencies Research (DEMBER) Lab, University of California–San Diego Health System; **Kimberly Nordstrom, MD, JD**, Assistant Professor, University of Colorado, Denver; Psychiatric Emergency Service, Denver Health Medical Center, Denver, CO; **Scott L. Zeller, MD**, Chief, Psychiatric Emergency Services, Alameda Health System, Oakland, CA.

Emergency Medicine Reports’ “Rapid Access Guidelines.” Copyright © 2014 AHC Media LLC, Atlanta, GA. **Editors:** Sandra M. Schneider, MD, FACEP, and J. Stephan Stapczynski, MD. **Editorial Director:** Lee Landenberger. **Executive Editor:** Shelly Morrow Mark. **Managing Editor:** Leslie Hamlin. For customer service, call: **1-800-688-2421**. This is an educational publication designed to present scientific information and opinion to health care professionals. It does not provide advice regarding medical diagnosis or treatment for any individual case. Not intended for use by the layman.

Emergency Medicine Reports

Practical, Evidence-Based Reviews in Emergency Care

Volume 34

www.emreports.com

2013 Subject Index: Volume 34, Numbers 1-26

Entries are organized alphabetically by subject matter and key words, with entries followed by the issue number and page number (e.g., issue number 2, page 20 would be listed as 2:20). Tables are indicated by a lowercase t, figures by a lowercase f.

A

- AAST.** *See* American Association for the Surgery of Trauma
- Abscesses, lung,** 17:205–206, 205f
- Abuse**
- burn patterns consistent with, 25:293–294
 - documentation of suspected abuse, 25:294, 294t, 297
 - drug misuse or abuse, 5:50t
 - features of bruises suggestive of, 25:291, 291t
 - opioid use/abuse, 5:49–58
 - physical abuse of children, 25:289–299
 - of prescription drugs, 5:50–51, 50t
 - of prescription opioids, 5:49, 50–51
 - red flags for, 25:294–295, 295t
 - risk factors for, 25:290
 - sexual, 25:296
- Abusive head trauma (AHT),** 25:293
- ACCF.** *See* American College of Cardiology Foundation
- Acclimatization,** 13:147
- ACD.** *See* Allergic contact dermatitis
- Acetaminophen (Tylenol),** 7:77, 77t
- Acetaminophen/hydrocodone (Lortab/Norco)**
- equianalgesic dosing, 5:53t
 - for pediatric pain management, 7:77t
- Acetaminophen/oxycodone (Percocet)**
- equianalgesic dosing, 5:53t
 - for pediatric pain management, 7:77t
- Acetazolamide,** 13:150t, 151, 152
- Acetylsalicylic acid (ASA).** *See* Aspirin
- ACL.** *See* Anterior cruciate ligament
- Acne, neonatal,** 4:39
- ACS.** *See* Acute coronary syndrome
- Actiq (transmucosal fentanyl),** 5:53t
- Activated charcoal,** 14:164
- Acute chest pain,** 18:209–219
- Acute coronary syndrome (ACS),** 18:209
- coronary artery calcium scoring and, 18:216–217
 - evaluation of, 18:215–216
 - ischemic, 18:211
 - suspected, 18:212, 212t
- Acute heart failure**
- history and physical examination in, 2:21
 - peripheral edema with, 2:15
- Acute mountain sickness (AMS),** 13:145, 148
- end-stage, 13:148t
 - Lake Louise criteria, 13:148, 148t
 - pathophysiology of, 13:147
 - prevention of, 13:148–149
 - risk factors for, 13:148, 149t
 - treatment of, 13:148–149, 152–153
- Acute myocardial infarction (AMI),** 18:209
- definition of, 18:209, 210, 210t
 - rapid AMI protocol, 18:213
- Acute pancreatitis**
- Beds Index for Severity of Acute Pancreatitis (BISAP), 6:65–66, 65t
 - causes of, 6:64t
 - management of, 6:67t
- Acute Physiology and Chronic Health Evaluation (APACHE II) scale,** 6:65
- Acute respiratory failure,** 16:191
- Acute severe asthma,** 16:181–194
- interventions for, 16:186t
 - markers of, 16:183, 183t
 - medications for, 16:188t
 - risk factors for, 16:181–182, 183t
- Acute trauma,** 23:273. *See also* Trauma
- Acute ulnar collateral ligament (UCL) injury,** 21:249
- Acyclovir,** 4:45, 15:174t
- Addiction,** 5:54t, 55
- Adenosine stress tests,** 3:31
- ADHD drugs,** 5:50t
- Adolescent history**
- key components, 15:171t
 - taking, 15:169–170
- Adolescents**
- general approach to female patients, 15:169–170
 - gynecologic complaints in, 15:169–179
 - risk factors for STIs in, 15:173
 - sexually transmitted infections in, 15:173
- Advance care plans,** 10:112, 112t
- Advance directives,** 10:110, 114–115
- Advocacy, child,** 25:297
- Affect, pseudobulbar (PBA),** 24:286
- Affordable Care Act,** 10:111
- AFO.** *See* Ankle-foot orthosis
- AHA.** *See* American Heart Association
- AHT.** *See* Abusive head trauma
- Air embolism, bronchovascular,** 19:222
- Alanine aminotransferase (ALT),** 6:63
- Albuterol,** 16:187, 188t
- Alcohol abuse,** 5:51
- Allergic contact dermatitis,** 4:41
- Alliance of States with Prescription Monitoring Programs,** 5:51
- Altavera,** 15:177t
- Alteplase,** 19:225, 226t
- Altered mental status,** 6:66
- Altitude illness**
- high altitude illness, 13:145–155
 - physiologic changes with altitude, 13:146–147
- Aluminum foam finger splints,** 21:252, 252f
- AMA.** *See* American Medical Association
- American Academy of Pain Medicine**

- (AAPM), 5:52
- American Association for the Surgery of Trauma (AAST)**, 9:101, 101t
- American College of Cardiology Foundation (ACCF)**, 3:32
- American College of Emergency Medicine**, 7:74
- American College of Emergency Physicians (ACEP)**
clinical policy on CT scan criteria for mild TBI, 11:124, 124t, 127
policy statement on advance directives and end-of-life care, 10:110
Washington Emergency Department Opioid Prescribing Guidelines, 5:55t,56
- American College of Physicians (ACP)**, 5:56–57
- American College of Surgeons Committee on Trauma**, 19:221
- American Congress of Rehabilitation Medicine**, 11:122
- American ginseng (*Panax quinquefolius*)**, 20:238
- American Heart Association (AHA) ACLS Guidelines**, 19:225
Guidelines for stroke recovery, 24:282
- American Medical Association (AMA)**, 5:56
- American Urological Association (AUA)**, 9:103–104
- Amethia**, 15:177t
- Amethia Lo (combination progestin and estrogen)**, 15:177t
- Amethyst (combination progestin and estrogen)**, 15:177t
- Aminophylline**, 16:188t, 189
- AMS**. *See* Acute mountain sickness
- Amylase**, 6:63
- Analgesics**
equianalgesic dosing charts, 5:52–54, 53t
for pediatric patients, 7:77, 77t, 78, 78t
for shoulder dislocation, 22:262
- Anasarca**, 2:13, 17t
- Anatomy**
coronary, 3:26
of intercostal nerve, 12:140f
penile, 9:97–98, 103f
of shoulder, 22:257
of testicle, 8:91–92, 91f
- Anesthetics**
inhalational, 16:191
local, 7:79–80, 79t
for pediatric patients, 7:78t, 79–80, 79t
topical, 7:80
volatile, 16:191
- Angina, unstable**, 18:209
- Angiography**
computed tomography angiography, 18:213–215
coronary computed tomographic angiography (CCTA), 18:209, 215, 215f, 216, 216t, 217
coronary computed tomography, 18:215, 215f
- Ankle-foot orthosis (AFO)**, 24:284
- Anterior cruciate ligament (ACL) injuries**, 23:270
- Anterior urethral injuries**, 9:101
- Anti-anxiety drugs**, 5:50t
- Antibiotics**
for atopic dermatitis, 4:44
for pancreatitis, 6:67
- Anticholinergic therapy**
for acute severe asthma, 16:187–188
for terminal secretions, 10:115–116
- Anticoagulants**, 11:125–126
oral, 14:163–165
- Antidiabetic drugs**
adverse effects of, 14:162
new, 14:161–162
overdose, 14:161–163
- Antifungal drugs, topical**, 4:41t
- Antimicrobials**. *See also* Antibiotics
for community-acquired pneumonia in children, 17:203
- Anti-platelet agents**, 11:125–126
- Antipsychotics**, 5:50t
- Anxiolytics**
abuse of, 5:50t
discharge/homecare instructions, 7:82
for pediatric patients, 7:80–81, 81t
- Apixaban overdose**, 14:163, 164
- Apnea**, 26:303
- Appendix testis**, 8:90
- Appropriate Use Criteria (AUC) for Cardiac Radionuclide Imaging**, 3:32
- APS**, 5:52
- Aristocort HP (triamcinolone acetonide)**, 4:40t
- Arm training, robot-assisted**, 24:284
- ASA (acetylsalicylic acid)**. *See* Aspirin
- Ascites**, 2:13, 17t
- Asian ginseng (*Panax ginseng*)**, 20:238
- Aspiration pneumonia**, 17:201
- Aspirin**, 13:152
- Assessment**. *See* Rapid Palliative Care Assessment
- Asthma**
acute severe, 16:181–194
Becker asthma score, 16:183, 184t
community-acquired pneumonia in children with, 17:199
complications of, 16:183, 185t
life-threatening episodes, 16:181, 182t
potentially fatal, 16:181–182, 182t, 183t
severity, 16:183, 184t, 185t
- Atherosclerosis**, 3:26–27
- Ativan (lorazepam)**, 7:80–81, 81t
- Atlanta Classification of Severe Acute Pancreatitis**, 6:65
- Atopic dermatitis**, 4:43–44, 44f
- Atrophy**, 4:39t
- Atropine**, 10:115
- “Aubergine sign,”** 9:99
- AUC criteria**. *See* Appropriate Use Criteria (AUC) for Cardiac Radionuclide Imaging
- Auto-PEEP**, 16:182–183, 190
- Azithromycin**, 15:175t, 176
- ## B
- Bacteremia**, 26:305
- Bacterial infections**
pneumonia, in children, 17:198t, 199, 200–201, 201t
serious bacterial infection (SBI), 26:305
vaginosis, 15:174t
- Bankart lesion**, 22:261, 263f
- BANs**. *See* Breath-actuated nebulizers
- Barium swallow, modified (MBS)**, 24:285, 285f
- Barometric pressure (Pb)**, 13:147
- Bechler, Joshua**, 20:235
- Becker asthma score**, 16:183, 184t
- Bedside dysphagia screening**, 24:284t, 285
- Bedside Index for Severity of Acute Pancreatitis (BISAP)**, 6:65–66, 65t
- Bedside ultrasound**, 22:263, 264f
- Bennett fractures**, 21:248–249, 248f
- Benzathine penicillin G**, 15:175t
- Benzocaine (Hurricane spray)**, 7:80
- Benzodiazepines**
abuse of, 5:50, 50t
for pain management in pediatric patients, 7:80–81, 81t
for painful procedures, 7:82
- Betamethasone dipropionate (Diprolene, Diprosone)**, 4:40t
- Betamethasone valerate (Valisone)**, 4:40t
- β₂-adrenergic agonists**, 16:186t, 187, 188t
- Bier block**, 7:80
- Bilevel positive airway pressure (BiPAP)**, 16:190
- Bioness L300**, 24:284
- Biotin**, 20:240
- BISAP**. *See* Bedside Index for Severity of Acute Pancreatitis

- Bite marks, 25:291
- Bitter orange (*Citrus aurantium*), 20:238
- Black dot tinea capitis, 4:42
- “Black salve,” 20:239
- Bleeding**
dysfunctional uterine bleeding (DUB), 15:171
intrathoracic hemorrhage, 19:222
retinal hemorrhage, 25:293, 296
subdiaphragmatic hemorrhage, 19:222
vaginal, 15:170–173
- Blood pressure, elevated.** *See* Hypertension
- Blood transfusion**, 14:164
- Blood urea nitrogen (BUN)**, 6:63
- Bloodroot** (*Sanguinaria canadensis*), 20:239
- “Blue dot” sign, 8:90
- Blunt trauma**
criteria for ED thoracotomy, 19:221
with recent loss of signs of life, 19:221
- Bobsledding**, 23:276
- Body-weight-supported treadmill training (BWSTT)**, 24:283
- “Bolus tracking,” 18:214
- Boxer’s fracture**, 21:252–253, 253f
- Brain injury, traumatic**
definition of, 11:121
inflicted, 25:293
mild, 11:121–128
- Breath-actuated nebulizers (BANs)**, 16:187
- Bronchitis, high altitude**, 13:153
- Bronchodilators**
for acute severe asthma, 16:186t
for RSV, 26:305–306, 306t, 308–309
- Bronchovascular air embolism**, 19:222
- Bronkaid®**, 20:238
- Bruises**
in children, 25:290–291
features suggestive of abuse, 25:291, 291t
- Buchanan, Vern**, 5:51
- Bucket handle fractures**, 25:292, 292f
- Buck’s fascia**, 9:98
- Bullae**, 4:38t
- Bupivacaine**, 7:79t
- Buprenorphine**, 14:159
- Buprenorphine overdose**, 14:159–160, 160f
- Burns**
child abuse, 25:293–294
cigarette, 25:293, 295
- Butterbur** (*Petasites hybridus*), 20:237
- Button batteries**, 1:5, 7–8
- Button battery ingestions**
complications of, 1:9
pediatric, 1:2–3, 7–8
“Buzzy”®, 7:80
- BWSTT.** *See* Body-weight-supported treadmill training
- Byetta™ (exenatide)**, 14:161–162
- Bypass, cardiopulmonary**, 19:227–228
- C**
- CACS.** *See* Coronary artery calcium scoring
- CAD.** *See* Coronary artery disease
- Caffeine**, 20:240
- Calcium**
coronary artery, 18:216–217
side effects of, 20:241
- CAM.** *See* Complementary and alternative medicine
- Canadian Cervical Spine Rule (CCS)**, 12:134–135, 136t
- Canadian CT Head Rule**, 11:124–125, 124t, 127
- Cancer pain**, 5:51, 56–57
- CAP.** *See* Community-acquired pneumonia
- Carbon monoxide poisoning**, 13:153
- Cardiac death**, 3:31f
- Cardiac muscle**, 18:209
- Cardiac radionuclide imaging**, 3:32
- Cardiac troponin assays**, 18:209–210, 210–211
- Cardiac troponins**
and chest pain management, 18:211–212, 212t
high-sensitivity (hs-cTn), 18:209–211, 212–213
in non-ischemic conditions, 18:211, 211t, 212
as preferred biomarker and diagnostic threshold, 18:210
rise and/or fall of, 18:211
and suspected ACS, 18:212, 212t
- Cardiolite®**, 3:28, 30
- Cardiomyopathy**
constrictive, 2:15–16
restrictive, 2:15–16, 20
- Cardiopulmonary bypass, emergency**, 19:227–228
- Cardiopulmonary resuscitation, extracorporeal (E-CPR)**, 19:227, 228
- Caregivers**, 10:112, 112t
- Cartilage**, 12:137
- CCS.** *See* Canadian Cervical Spine Rule
- CCTA.** *See* Coronary computed tomographic angiography
- Cefixime**, 15:176
- Ceftriaxone**, 15:175t, 176
- Center to Advance Palliative Care**, 10:117
- Cerebral edema, high-altitude (HACE)**, 13:145, 148t, 149–150
- Cervical spine injury**
Canadian Cervical Spine Rule (CCS), 12:134–135, 136t
plain film radiography of, 12:136–137, 137f, 138f
treatment of, 12:138
- Cervical strain**, 12:138
- Cesarean section, perimortem**, 19:223–224
- Chaparral toxicity**, 20:237
- Charcoal, activated**, 14:164
- Chest pain**
acute, 18:209–219
evaluation of, 18:211–212, 213–215
management strategies for, 18:211–212, 212t
- Chest radiography**
in children, 17:201t, 202
indications for, 12:139–140, 17:201t, 202
- Chest trauma**
admission criteria, 12:140–141
discharge criteria, 12:141
history of, 12:139
minor, 12:139–141
physical examination of, 12:139
treatment of, 12:140
- Child abuse**
ancillary studies, 25:296
clinical evaluation of, 25:294–295
diagnosis of, 25:296, 297t
differential diagnosis, 25:295–296
epidemiology of, 25:289–290
evaluation for, 25:294
imaging considerations, 25:296, 296t
medical, 25:294
medico-legal considerations, 25:296–297
physical, 25:289–299
psychosocial evaluation of, 25:296
risk factors for, 25:290
sequelae of, 25:290
what to do when considering a diagnosis of, 25:296–297, 297t
- Child advocacy**, 25:297
- Children.** *See also* Infants
bacterial pneumonia in, 17:198t, 199
buprenorphine overdose in, 14:159–160, 160f
community-acquired pneumonia in, 17:197–206, 198t, 199t, 200t, 204t
distal radius fractures in, 21:245
esophageal foreign body obstruction

- in, 1:3–4, 3f
 foreign body ingestions in, 1:1–10, 2f, 3t, 4f, 5f, 6f
 fractures in, 25:291–292
 hand and wrist injuries in, 21:245, 246
 ILE therapy for, 14:161
 injuries to, 25:290–291
 maltreatment of, 25:289
 neglect of, 25:289
 pain management for, 7:73–83, 76t
 physical abuse of, 25:289–299
 pneumonia in, 17:197, 201t
 RSV in, 26:301, 303, 304–305, 305–308, 306t, 307f
 skin rashes in, 4:37–46
 viral pneumonia in, 17:200, 203
- China**, 20:233
- Chinese licorice (*Glycyrrhiza uralensis*)**, 20:238
- Chinese traditional medicine**, 20:234–235
- Chlamydia**
 alternative treatment options, 15:174–176
 testing for, 15:173–174
 treatment of, 15:173, 174, 175t
- Chromium**, 20:241
- Chronic disease**, 5:51, 51t
- Chronic Hill-Sachs deformity**, 22:261, 262f
- Chronic mountain sickness**, 13:153
- Chronic pain**
 incidence of, 5:51, 51t
 management of, 5:51
 strategies for dealing with, 5:56
- Chronic pancreatitis**, 6:68–69
- Ciclopirox (Loprox)**, 4:41t
- Cigarette burns**, 25:293, 295
- CIMT**. *See* Constraint-induced movement therapy
- CIN**. *See* Contrast-induced nephropathy
- Cirrhosis**
 history and physical examination of, 2:20
 peripheral edema with, 2:17
- Clavicle fractures**, 23:272–273
- Clindamycin**, 15:174t
- Clobetasol propionate (Temovate)**, 4:40t
- Clopidogrel**, 11:125–126
- Clotrimazole (Lotrimin)**, 4:41t
- CNS stimulants**, 5:50t
- CNS trauma**
 to children, 25:292–293
 differential diagnosis, 25:296
- Cocaine**, 5:51
- Cocaine toxicity**, 14:160
- Coccyx fracture**, 23:274, 274t
- Code of Ethics (AMA)**, 5:56
- Codeine**
 equianalgesic dosing, 5:53t
 equipotent opioid conversions, 10:115t
 for pain management in pediatric patients, 7:78
- Coefficient of variation (CV)**, 18:210
- Cognitive function**, 11:123
- Cognitive rehabilitation**, 24:285
- Coins, esophageal**, 1:5, 5f
- Cold sores**, 4:45
- Cold sprays (vapocoolant sprays)**, 7:76
- Colles' fracture**, 23:272
- Coma**, 11:122t
- Comfrey (*Symphytum officinale*, *Symphytum asperum*, and *Symphytum x uplandicum*)**, 20:237
- COMM**, 5:52t
- Community-acquired pneumonia in children**, 17:197–206
 causes of, 17:197, 198t, 199
 clinical manifestations of, 17:200, 200t
 complications of, 17:204t
 diagnostic clues, 17:199t
 differential diagnosis, 17:201–202
 evaluation of, 17:202
 management of, 17:202–203, 202t
 monitoring, 17:203–204
 prognosis for, 17:206
 prolonged, 17:201
 viral causes of, 17:199
- Complementary and alternative medicine (CAM)**
The Professional's Handbook of Complementary and Alternative Medicines, 20:236
 use of, 20:233, 235f, 236f, 237f
- Comprehensive Stroke Centers**, 24:282
- Computed tomography**
 ACEP clinical policy on criteria for mild TBI, 11:124, 124t, 127
 Canadian CT Head Rule, 11:124–125, 124t, 127
 multi-detector (MDCT), 18:213–214
 of subdural hematoma, 23:272f
- Computed tomography angiography**
 considerations for performing, 18:214
 coronary (CCTA), 18:209, 215, 215f, 216, 216t, 217
 in evaluation of chest pain, 18:213–215
 quality of, 18:213–214
 “triple rule out” (TRO-CTA), 18:214–215
- Concussion**
 ice hockey injuries, 23:274–275
 post-concussive syndrome, 11:126
 signs and symptoms of, 23:273t, 274–275
- Confidentiality**
 with emergency contraception, 15:178
 updates on issues of, 15:170
- Congenital heart disease**, 17:199
- Constraint-induced movement therapy (CIMT)**, 24:283
- Constrictive cardiomyopathy**, 2:15–16
- Constrictive pericarditis**, 2:15–16, 20
- Contact dermatitis**, 4:41–42
- Contraception, emergency**, 15:176–178, 176t
- Contrast-induced nephropathy**, 18:214
- Copper intrauterine device (IUD)**, 15:176
- Coronary anatomy**, 3:26
- Coronary angiography**
 CT, 18:209, 215, 215f, 216, 216t, 217
 invasive, 18:215
- Coronary artery calcium scoring (CACs)**, 18:216–217
- Coronary artery disease (CAD)**, 3:26–27
 false-negative stress MPI tests in, 3:29t, 30
 identification of, 18:209
 non-invasive tests for, 3:30, 30t
- Coronary computed tomographic angiography (CCTA)**, 18:209, 215, 215f, 217
 considerations for patient selection, 18:216, 216t
 current evidence for, 18:216, 216t
 long-term consequences of, 18:216
 short-term benefits of, 18:216
- Corticosteroids**
 abuse of, 5:51
 for acute severe asthma, 16:186–187, 186t, 188t
 for atopic dermatitis, 4:44
 for RSV, 26:306, 306t
 topical, 4:39–40, 40t
- Cradle cap**, 4:39
- C-reactive protein (CRP)**, 6:63–64
- Creatine**, 20:240
- Cremasteric contraction**, 8:92
- Cremasteric reflex**, 8:92

Cross-country skiing injuries, 23:272t, 273–274

CT. *See* Computed tomography

CT Severity Index (CTSI), 6:64

CTA. *See* Computed tomography angiography

CTSI. *See* CT Severity Index

Cultures, 17:202

Cunningham technique, 22:260, 260t

Cupping, 25:295

Current Good Manufacturing Practices (FDA), 20:235

CV. *See* Coefficient of variation

Cystic fibrosis, 17:199

D

Dabigatran overdose, 14:163, 164, 165

Dartos fascia, 9:98

Datura stramonium (jimsonweed), 20:239–240

Decision-making capacity, 10:112, 112t

Deep sedation, 7:81–82

Dehydration, 16:185

Dental injuries, 23:275

Depression, 24:286t

Dermatitis

atopic, 4:43–44, 44f

contact, 4:41–42

seborrheic, 4:39–40, 40f

Dermatomes, 12:134, 135f

Desonide (DesOwen), 4:40t

DesOwen (desonide), 4:40t

Detergent pod ingestion, 14:157–159

Dexamethasone

for high altitude illness, 13:150t, 151, 152

for high-altitude cerebral edema, 13:150

for high-altitude pulmonary edema, 13:150

Dextrose, 14:163

Diabetes, 14:161

Diagnosis Intractability Risk Efficacy Tool (DIRE), 5:52, 52t

Diaper rash, 4:41–42, 42f

Diazepam (Valium), 7:80–81, 81t

Dietary Supplement Health and Education Act of 1994 (DSHEA), 20:234

Dietary supplements, 20:233–242

Dilaudid (hydromorphone)

equianalgesic dosing, 5:53t

for pain management in pediatric patients, 7:78, 78t

DILI. *See* Drug-induced liver injury

Dipeptylpeptidase-4 (DPP-4), 14:162

Diprolene (betamethasone dipropionate), 4:40t

Diprosone (betamethasone dipropionate), 4:40t

DIRE. *See* Diagnosis Intractability Risk Efficacy Tool

Dislocation

finger, 21:251–252

proximal interphalangeal joint (PIP), 21:251–252, 251f

shoulder, 22:257–266, 258f

thumb, 21:251–252, 251f

Distal radius fractures, 21:245

Distracting injuries, 12:135–136

Distraction, voluntary, 7:76

DNR orders, 10:114–115

Dobutamine stress test, 3:30–31

Doctor shopping, 5:55

Documentation of suspected abuse, 25:294, 294t, 297

Dorsal avulsion fracture, 21:251

Dorsal nerve block, penile, 9:103

Dosing, equianalgesic, 5:52–54, 53t

Downhill skiing injuries, 23:270–271

head injuries, 23:271

multisystem trauma, 23:271

shoulder injuries, 23:270–271, 271t

spinal injuries, 23:271

Doxycycline

for epididymitis, 8:88–89

for gonorrhea, 15:176

for gynecologic infections, 15:175t

DPP-4. *See* Dipeptylpeptidase-4

Dropsy, 2:13

Drug misuse or abuse, 5:49–50, 50t

Drug overdose, 5:50–51

Drug-induced liver injury (DILI), 20:237

Drug-induced peripheral edema, 2:17

DSHEA. *See* Dietary Supplement Health and Education Act of 1994

Dual isotope studies, 3:33

DUB. *See* Dysfunctional uterine bleeding

Dying patients, 10:115

Dynamic hyperinflation, 16:182–183

Dysfunctional uterine bleeding (DUB), 15:171, 172t

Dysphagia, 24:284t, 285

Dyspnea, 2:17t

E

Echinacea purpurea (purple cone-

flower), 20:239

ECMO. *See* Extracorporeal membrane oxygenation

Eczema, 4:43–44

Eczema herpeticum, 4:45, 45f

ED. *See* Emergency Department Edema

clinical presentations, 2:15, 16f

definition of, 2:13

idiopathic, 2:18–19, 21

localized, 2:21

lymphedema, 2:17–18, 21

myxedema, 2:18

peripheral, 2:13–23

physical findings, 2:17t

pitting, 2:20

pulmonary, 2:17t

EDT. *See* Emergency department thoracotomy

Education in Palliative and End-of-Life Care for Emergency Medicine (EPEC-EM), 10:110, 117

“Eggplant sign,” 9:99

Ehlers-Danlos syndrome, 25:295

Elderly. *See* Older adults

Eleutherococcus senticosus (Siberian ginseng), 20:238

Elixir Sulfanilamide, 20:234

Ella (ulipristal acetate), 15:176, 177t

Elocon (triamcinolone acetonide), 4:40t

Embolism

bronchovascular air, 19:222

pulmonary (PE), 19:224–225

Emergency cardiopulmonary bypass, 19:227–228

Emergency contraception, 15:176–178

indications for, 15:176, 176t

oral contraceptives that can be used for, 15:176, 177t

Emergency Contraception website, 15:176

Emergency department

ACS evaluation in, 18:215–216

avoiding transfers to, 10:113–114

chest pain evaluation in, 18:211–212, 214–215

coronary artery calcium scoring and ACS in, 18:216–217

illness trajectories for patients in, 10:111–112

ouchless, 7:82

Emergency department thoracotomy (EDT), 19:221–223

indications for, 19:221, 223t

survivability, 19:223, 224t

- Emergency medicine**
 culture of, 10:112
 as expanding field, 10:110–111
- Emergency palliative care**, 10:109–110, 116–117
 barriers to, 10:116, 116t
- Emergency physicians**, 24:281
- EMLA (eutectic mixture of lidocaine and prilocaine)**, 7:79t, 80
- Empyema**, 17:205–206, 205f, 206f
- End-expiratory pressure (EPAP)**, 16:190
- End-of-life care**, 10:110, 115–116
- Education in Palliative and End-of-Life Care for Emergency Medicine (EPEC-EM)**, 10:110, 117
 practice guidelines for, 5:56–57
- Endoscopic retrograde cholangiopancreatography (ERCP)**, 6:67
- Endoscopic ultrasound**, 6:67–68
- End-stage acute mountain sickness**, 13:148t
Enzyte®, 20:238
- Eosinophilia-myalgia syndrome**, 20:234
- EPAP (end-expiratory pressure)**, 16:190
- EPEC-EM**. *See* Education in Palliative and End-of-Life Care for Emergency Medicine
- Ephedra**, 20:235, 238
- Epididymitis**, 8:88–89
- Epididymo-orchitis**, 8:88–89
- Epinephrine**
 for acute severe asthma, 16:187
 LET (lidocaine, epinephrine, and tetracaine), 7:79t, 80
 for pain management in pediatric patients, 7:79t, 80
- Equianalgesic dosing charts**, 5:52–54, 53t
- ERCP**. *See* Endoscopic retrograde cholangiopancreatography
- Erectile dysfunction**, 20:238
- Erection**, 9:98
- Erosions**, 4:39t
- Erythema multiforme**, 25:295
- Erythema toxicum neonatorum (ETN)**, 4:39, 39f
- Erythromycin**, 15:176
- Eskimo technique**, 22:260t, 261
- Esophageal foreign bodies**
 in children, 1:3–4, 3f, 3t, 4f, 5f
 diagnostics, 1:4f, 5, 5f
 symptoms, 1:3t, 4
- Estradiol, ethinyl**, 15:172t
- Estrogen and progestin pills**, 15:177t
- Ethinyl estradiol**, 15:172t
- ETN**. *See* Erythema toxicum neonatorum
- Europe**, 20:233
- Excoriation**, 4:39t
- Exenatide (Byetta™)**, 14:161–162
- Exercise testing**
 alternatives to, 3:30–31
 normal, 3:27–28, 27f
 stress tests, 3:27–28, 27f, 29
- Extracorporeal cardiopulmonary resuscitation (E-CPR)**, 19:227, 228
- Extracorporeal membrane oxygenation (ECMO)**, 19:227–228
- Extreme altitude exposure**, 13:145–146
- Extreme measures**, 19:221–231
- F**
- “Faces” pain scale**, 7:73
- Facial injuries**, 25:294
- Factor VIIa, recombinant (rFVIIa)**
 for oral anticoagulant overdose, 14:164, 165
 for rapid reversal of INR, 11:126
- Falls**, 12:133
- Famciclovir**, 15:174t
- Family issues**, 7:75–76
- FDP**. *See* Flexor digitorum profundus
- FEIBA**, 14:165
- Females, adolescent**, 15:169–179
- Fentanyl (Sublimaze)**
 equianalgesic dosing, 5:53t
 equipotent opioid conversions, 10:115t
 for pain management in pediatric patients, 7:78, 78t, 79
 transdermal, 5:53t
 transmucosal (Actiq), 5:53t
- Fentanyl patch (transdermal fentanyl)**, 5:53t
- FES**. *See* Functional electrical stimulation
- Fever blisters**, 4:45
- Fiber supplements**, 20:238
- Fibrinolytics**
 dosing, 19:226t
 for pulmonary embolus, 19:224–225
- “Finger breadth rule,”** 19:224
- Finger buddy taping**, 21:253f
- Finger dislocations**, 21:251–252
- Fish oil**, 20:238
- Fissures**, 4:39t
- FLACC (faces, legs, activity, cry, consolability) scale**, 7:73–74
- Flax seeds**, 20:238
- Flexor digitorum profundus (FDP) injury**, 21:251
- Fluconazole**, 15:174t
- Fluid balance abnormalities**, 16:185
- Fluid resuscitation**, 6:66–67
- Fluid therapy**, 6:66–67
- Flumazenil (Romazicon)**, 7:80–81
- Fluocinolone**, 4:44
- Fluocinolone acetonide (Synalar)**, 4:40t
- Fluocinonide (Lidex)**, 4:40t
- Food, Drug, and Cosmetic Act of 1938**, 20:233–234
- Food and Drug Administration (FDA)**
 “187 Fake Cancer ‘Cures’ Consumers Should Avoid,” 20:239
 Current Good Manufacturing Practices, 20:235
 regulation of herbal and supplemental medications by, 20:234
- Foot drop**, 24:284
- Forced ingestion**, 25:294
- Foreign body ingestions**
 esophageal, 1:3–4, 3f, 3t, 5f
 pathophysiology of, 1:2–4
 pediatric, 1:1–10, 2f, 4f, 5f, 6f
 removal options, 1:8–9
- Fournier, Jean-Alfred**, 8:86
- Fournier’s gangrene**, 8:85–87, 87f
- Fractures**
 Bennett, 21:248–249, 248f
 boxer’s fracture, 21:252–253, 253f
 in children, 25:291–292
 clavicle, 23:272–273
 of coccyx, 23:274, 274t
 discharge criteria, 12:141
 distal radius, 21:245
 hand/wrist, 21:245
 metacarpal, 21:252t
 metaphyseal bucket handle fracture, 25:292, 292f
 open, 23:274, 274t
 penile injury, 9:97–99, 98f
 phalanx, 21:252, 252t
 posterior rib, 25:292, 292f
 proximal thumb metacarpal, 21:245
 rib, 12:139–140, 140–141, 25:292, 292f
 Rolando, 21:249, 249f
 scaphoid, 21:245, 247–248
 with shoulder dislocation, 22:261
 skeletal, 25:295
 skull, 25:292
 thumb metacarpal, 21:248–249
 Tuft, 21:250, 250f
 upper extremity, 21:245
- Frailty**, 10:111

Fresh frozen plasma, 11:126
Frostbite, 13:153
Frozen shoulder, 23:271, 273
Functional electrical stimulation (FES), 24:283–284
Furosemide, 2:22
Future directions, 18:209–219

G

Gabapentin, 13:152
Gait training, 24:283
Gamekeeper or skier's thumb, 23:270–271
Gamma cameras, 3:27
Gangrene, Fournier's, 8:85–87, 87f
Garlic, 20:238
Gastroesophageal reflux disease, 17:199
Gate theory, 7:76
for pain blockade in pediatric patients, 7:80
Gated SPECT imaging, 3:30
GCS. *See* Glasgow Coma Scale
Gender differences, 21:246
Genital emergencies, 8:85
male, 8:85–94, 9:97–107
Genital herpes simplex virus (HSV) infection, 15:174t
GERD. *See* Gastroesophageal reflux disease
Germany, 20:233
Gila monsters, 6:62
Ginger, 20:238
Ginkgo biloba
for high altitude illness, 13:152
toxicities, 20:238
Ginseng, 20:238
GIP. *See* Glucose-dependent insulinotropic peptide
Glasgow Coma Scale, 11:122, 122t
GLP-1. *See* Glucagon-like peptide-1 (GLP-1)
Glucagon-like peptide-1 (GLP-1), 14:161–162
Glucose-dependent insulinotropic peptide (GIP), 14:161–162
Glycopyrrolate, 10:115
***Glycyrrhiza glabra* (licorice)**, 20:238
***Glycyrrhiza uralensis* (Chinese licorice)**, 20:238
Goals of care, 10:112
Gonorrhea
alternative treatment options, 15:174–176
prevalence of, 15:173
testing for, 15:173–174
treatment of, 15:173, 174, 175t

Griseofulvin, 4:42
Gutter splints, 21:253f
Gynecologic complaints, 15:169–179
Gynecologic examination, adolescent, 15:170
Gynecologic infections, 15:173, 174t–175t

H

HACE. *See* High-altitude cerebral edema
HAL. *See* High altitude illness
Hand injuries, 21:245–254
epidemiology of, 21:246
etiology of, 21:246–247
fractures, 21:245
pathophysiology of, 21:246–247
Hand-held metal detectors (HHMDs), 1:7
HAPE. *See* High-altitude pulmonary edema
HAPS. *See* Harmless Acute Pancreatitis Score
Harmless Acute Pancreatitis Score (HAPS), 6:65–66, 66t
Hatchet deformity, 22:261
Head injuries. *See also* Traumatic brain injury
abusive trauma, 25:293
in downhill skiing, 23:271
epidemiology of, 11:121
in older adults, 23:276
patterns of, 23:271t
in snowboarding, 23:271–272
Headache pain, 5:51
Heart failure
acute, 2:15
history and physical examination in, 2:21
Helium-oxygen mixtures (heliox), 16:189
Hematocrit, 6:63
Hematoma
subdural, 23:272, 272f
subungual, 21:250, 251f
Hemodialysis, 14:164
Hemorrhage
intrathoracic, 19:222
retinal, 25:293, 296
subdiaphragmatic, 19:222
Hemorrhagic shock, 19:222
Herbal medications
“187 Fake Cancer ‘Cures’ Consumers Should Avoid” (FDA), 20:239
complications of, 20:233–242
gastrointestinal toxicity, 20:237–238
regulation of, 20:233–236
spending on, 20:233
use of, 20:233
Herbal supplements, 20:236–237
Herbs at a Glance (NCCAM), 20:236
Herpes labialis, 4:45
Herpes simplex virus (HSV) infections
genital, 15:174t
management of, 4:45, 15:174t
Herpetic gingivostomatitis, 4:45
Herpetic whitlow, 4:45, 45f
HHMDs. *See* Hand-held metal detectors
High altitude
categories, 13:147t
extreme altitude, 13:145
health considerations, 13:153
physiologic changes with, 13:146–147
problems exacerbated by, 13:147t
sample locations, altitudes, and PIO₂, 13:145, 146t
High altitude bronchitis, 13:153
High altitude illness, 13:145–155
extreme altitude exposure, 13:145–146
medications for, 13:150t, 151–152
treatment modalities for, 13:152–153
High altitude renal syndrome, 13:153
High altitude retinopathy, 13:153
High-altitude cerebral edema (HACE), 13:145, 149–150
Lake Louise criteria, 13:148t
treatment of, 13:152–153
High-altitude pulmonary edema (HAPE), 13:145, 150–151
incidence of, 13:150–151, 150t
Lake Louise criteria, 13:148t
pathophysiology of, 13:147–148
treatment of, 13:152–153
High-frequency oscillatory ventilation, 16:191
High-sensitivity cardiac troponin (hs-cTn) assays, 18:209–211, 212
analytical performance and sensitivity of, 18:212, 213f
negative predictive value, 18:212–213
positive predictive value, 18:213
rapid AMI protocol, 18:213
serial sampling, 18:213
Hill-Sachs lesion, 22:261, 262f, 263f
reverse, 22:261, 262f
Hippocratic method, 22:260t
History taking
with adolescent female patients,

15:169–170, 171t
in evaluation for child abuse, 25:294
for suspected STIs, 15:173

HIV. *See* Human immunodeficiency virus

Hospice, 10:111, 112

Hospice care, 10:111

“Hot dot” sign, 8:90

H.R. 1065: Pill Mill Crackdown Act of 2011, 5:51

hs-cTn. *See* High-sensitivity cardiac troponin

HSV. *See* Herpes simplex virus

HTS. *See* Hypertonic saline

Human immunodeficiency virus (HIV) infection, 15:175t

Hurricane spray (benzocaine), 7:80

Hydrocodone

acetaminophen/hydrocodone (Lortab/Norco), 5:53t, 7:77t
equianalgesic dosing, 5:53t
equipotent opioid conversions, 10:115t
for pediatric pain management, 7:78

Hydrocodone abuse, 5:50, 50t

Hydrocortisone (Hytone), 4:40t, 44

Hydrocortisone butyrate (Locoid), 4:40t

Hydrocortisone valerate (Westcort), 4:40t

Hydromorphone (Dilaudid)

equianalgesic dosing, 5:53t
equipotent opioid conversions, 10:115, 115t
for pediatric pain management, 7:78, 78t

Hydropsy, 2:13

Hydrothorax, 2:13

Hyperbaric oxygen therapy

for high-altitude illness, 13:152–153
for high-altitude pulmonary edema, 13:150

Hypercapneic ventilatory response (HCVR), 13:147

Hyperglycemia, 16:185

Hypericum perforatum (St. John’s wort), 20:239

Hyperinflation, dynamic, 16:182–183

Hypertension, pulmonary, 2:16–17, 13:147, 147t

Hypertonic saline, 26:306, 306t

Hypnosis, 7:76

Hypokalemia, 16:184

Hypoproteinemia, 2:17

Hypothermia, 13:153
induced, 19:225–227

Hypothyroidism, 2:21

Hypoxemia, 16:183–184

Hypoxic ventilatory response (HVR), 13:147

Hytone (hydrocortisone), 4:40t

I

Ibuprofen

for high altitude illness, 13:150t, 152
for pain management in pediatric patients, 7:77

for pediatric pain management, 7:77t

ICD. *See* Irritant contact dermatitis

Ice skating injuries, 23:274

ICH. *See* Intracranial hemorrhage

ILE. *See* Intravenous lipid emulsion

Illicit drugs, 5:50t

Illness trajectories, 10:111–112

Imaging. *See also* specific modalities

for child abuse, 25:296, 296t
for community-acquired pneumonia in children, 17:202
myocardial perfusion imaging, 3:25–34
of shoulder dislocation, 22:262–264, 262f, 263f

Immunodeficiency

community-acquired pneumonia in children with, 17:199
HIV infection, 15:175t

Improving Palliative Care in Emergency Medicine Project (IPAL-EM), 10:117

Incretin enhancers, 14:161–162

Incretin mimetics, 14:161–162

Indian snakeroot (*Rauwolfia serpentina*), 20:239

Indian traditional medicine, 20:234–235

Infantile scabies, 4:40, 41f

Infants

neonatal herpes, 4:45
neonatal rashes, 4:38–41
neonatal scabies, 4:40–41
pneumonia in neonates, 17:197–199, 200
RSV in, 26:301, 303, 304–305, 305–308, 306t

Infection(s). *See also* specific diseases
gynecologic, 15:174t–175t
serious bacterial infection (SBI), 26:305
sexually transmitted, 15:173–176, 174t–175t

Infectious Diseases Society of America (IDSA), 8:87

Ingestions

detergent pod, 14:157–159
forced, 25:294
foreign body, pediatric, 1:1–10

Inhalational anesthetics, 16:191

Inhaled nitric oxide, 16:191

Injury

acute ulnar collateral ligament (UCL), 21:249

to children, 25:290–291

cross-country skiing injuries, 23:272t

distracting injuries, 12:135–136

facial, 25:294

to flexor digitorum profundus (FDP), 21:251

head injury patterns, 23:271t

ice hockey, 23:274–275

ice skating, 23:274

mild traumatic brain injury, 11:121–128

penile fracture, 9:97–99, 98f

penile zipper injuries, 9:104, 104f

phalanx, 21:250–251

skeletal, 25:292

skier’s thumb, 21:245, 249–250, 249f, 23:270–271, 273

sledding, 23:275–276

snowboarding, 23:271–273

snowmobiling, 23:275

spinal cord level of, 12:133–134, 134f, 136–137, 137f

thumb axis, 21:245–246

urethral injuries, 9:99–102, 100f

winter sports injuries, 23:269–278

wrist and hand, 21:245–254

Inpatient rehabilitation facilities (IRFs), 24:282

Insomnia drugs, 5:50t

Inspiratory pressure (IPAP), 16:190

Intercostal nerve block, 12:140, 140f

International normalization ratios (INR), 11:125–126

Intracranial hemorrhage

delayed, 11:126

immediate traumatic, 11:126

Intrathoracic hemorrhage, 19:222

Intrauterine device (IUD), 15:176

Intravenous lipid emulsion (ILE), 14:160

new uses, 14:160–161

in pediatric patients, 14:161

risks/complications of, 14:161

Intrinsic positive end-expiratory pressure (PEEPi), 16:182–183

Invasive coronary angiography, 18:215

Ionizing radiation, 3:33

IPAL-EM. *See* Improving Palliative Care in Emergency Medicine Project

Ipratropium bromide, 16:186t, 188t

IRFs. *See* Inpatient rehabilitation facilities

Iron, 13:152

Irritant contact dermatitis, 4:41–42

Irritant diaper dermatitis, 4:41–42, 42f
Ischemia, 3:26, 26f
Ischemic heart disease, 18:209
Isoflurane, 16:191
IUD. *See* Intrauterine device
IV contrast reactions, 18:214

J

Januvia™ (sitagliptin), 14:162
Jersey finger, 21:251
Jimsonweed (*Datura stramonium*), 20:239–240
Jock itch, 4:42–43
The Joint Commission, 24:282
J-tip®, 7:80

K

Kava kava, 20:237–238
Kefauver-Harris Drug Amendments, 20:234
Kenalog (triamcinolone acetonide), 4:40t
Keratitis, ultraviolet, 13:153
Ketamine
for acute severe asthma, 16:189–190, 190
for painful procedures, 7:81–82
for pediatric pain management, 7:78t
Ketoconazole (Nizoral), 4:41t, 42, 43
Ketorolac (Toradol), 7:77, 78t
Knee pain, 5:51
Knee sprains, 23:270
Koher method, 22:259, 260t

L

Labels, 20:234
Lachman test, 23:270
Lactic acidosis, 16:184
LAD artery. *See* Left anterior descending artery
Lake Louise criteria, 13:148
Lamisil (terbinafine), 4:41t
Language rehabilitation, 24:284–285
L-arginine, 20:238
Laundry detergent pod ingestion, 14:157–159
LCX artery. *See* Left circumflex artery
Left anterior descending (LAD) artery, 3:26
Left circumflex (LCX) artery, 3:26
Left ventricle anterior wall defect, 3:27f, 28f, 29
Left ventricle apical wall defect, 3:27f
Left ventricle inferior wall defect,

3:27f

Legal considerations

for child abuse, 25:296–297
for emergency contraception, 15:178
Lessina (combination progestin and estrogen), 15:177t

LET (lidocaine, epinephrine, and tetracaine), 7:79t, 80

Leukotriene A4 (LTA4), 16:190
Leukotriene modifiers, 16:188t, 190

Levalbuterol (R-albuterol), 16:187

Leverage methods, 22:259–260

Levofloxacin, 15:176

Levonorgestrel (Plan B/Next Choice)

contraindications to, 15:178
for emergency contraception, 15:176, 177t, 178

Levora (combination progestin and estrogen), 15:177t

Lexiscan® (regadenoson) stress tests, 3:31

Lichenification, 4:39t

Licorice (*Glycyrrhiza glabra*), 20:238

Lidex (fluocinonide), 4:40t

Lidocaine (LET, LMX4, EMLA)

for pediatric pain management, 7:79–80, 79t

for shoulder dislocation, 22:262

Life-limiting illness, 10:111

Life-threatening situations, 19:221–231

Ligands, 3:25

Limit of detection (LoD), 18:210

Linagliptin, 14:162

Lipase, 6:63

“Lipid sink” theory, 14:160

Liquid detergent pods (liquid tabs, sachets, or capsules), 14:157

Liraglutide, 14:162

Liver injury, drug-induced (DILI), 20:237

LMX4 (lidocaine embedded within liposomes), 7:79t

for pain management in pediatric patients, 7:80

Local anesthetics

for pediatric pain management, 7:79–80, 79t

for penile dorsal nerve block, 9:103

Localized edema, 2:21

Locoid (hydrocortisone butyrate), 4:40t

LoD. *See* Limit of detection

Lo/Ovral (combination progestin and estrogen), 15:177t

Loprox (ciclopirox), 4:41t

Lorazepam (Ativan)

for pediatric pain management, 7:80–81, 81t

for tachypnea, 10:116

Lortab/Norco (acetaminophen/hydrocodone)

equianalgesic dosing, 5:53t

for pediatric pain management, 7:77t

Lotrimin (clotrimazole), 4:41t

Low back pain, 5:51

Low-Ogestrel (progestin and estrogen), 15:177t

L-tryptophan, 20:234

Luge, 23:276

Lung abscesses, 17:205–206, 205f

Lymphedema, 2:17–18, 18f, 21

M

Ma huang (*Ephedra sinica*), 20:235, 238

Macules, 4:38t

Magnesium

for acute severe asthma, 16:188–189
complications of, 20:241

Magnesium sulfate, 16:186t, 188t, 189

Magnetic resonance imaging

of minor neck trauma, 12:136

of shoulder dislocation, 22:263–264, 263f

Magnetic retrograde cholangiopancreatography (MRCP), 6:67

Male enhancement, 20:238

Male genital emergencies, 8:85–94, 9:97–107

Male urethra, adult, 9:99–100

Mallet finger, 21:251

Maltreatment

of children, 25:289

definition of, 25:289

Manchin, Joe, 5:51

Manganese, 20:241

Marijuana, 5:51

Massive intrathoracic hemorrhage, 19:222

Mauna Kea, 13:145

McGill Quality of Life index, 10:110

MCL. *See* Medial collateral ligament

MDCT. *See* Multi-detector computed tomography

Mechanical ventilation

for acute severe asthma, 16:190–191
for children, 16:191

Medial collateral ligament (MCL) injuries, 23:270

Medical child abuse, 25:294

Medications. *See also* specific drugs

and medications
antibiotics, 4:44, 6:67
anticholinergics, 10:115–116, 16:187–188
anticoagulants, 11:125–126
antidiabetic drug overdose, 14:161–163
antimicrobials, 17:203
anti-platelet agents, 11:125–126
anxiolytics, 5:50t, 7:80–81, 81t, 82
drug-induced liver injury (DILI), 20:237
drug-induced peripheral edema, 2:17
for high altitude illness, 13:150t, 151–152
misuse or abuse of, 5:49–50, 50t
nonsteroidal anti-inflammatory drugs (NSAIDs), 7:77, 77t, 78t
oral anticoagulants, 14:163–165
oral contraceptive pills (OCPs), 15:172t, 176, 177t
for pain management in pediatric patients, 7:76–77
pharmacologic anxiolysis, 7:80–81
prescription drug abuse, 5:49, 50–51, 50t, 52t
topical anesthetics, 7:80
topical antifungal drugs, 4:41t
topical corticosteroids, 4:39–40, 40t

Medico-legal considerations
for child abuse, 25:296–297
for emergency contraception, 15:178

Meperidine, 10:115t

Metabolic acidosis, 16:184

Metacarpal fractures
boxer's fracture, 21:252–253, 253f
splints for, 21:252t
thumb, 21:245, 248–249, 252t

Metal detectors, hand-held (HHMDs), 1:7

Metaphyseal fractures, 25:292, 292f

Metered-dose inhalers (MDIs), 16:187

Methadone (Dolophine)
equianalgesic dosing, 5:53t
for pediatric pain management, 7:78

Methamphetamines, 5:51

Methylprednisolone
for acute severe asthma, 16:186
for cervical spine injury, 12:138

Metoclopramide, 14:162

Metronidazole, 15:174t

MI. *See* Myocardial infarction

Miconazole (Monistat), 4:41t

Midazolam (Versed)
for painful procedures, 7:82
for pediatric pain management, 7:80–81, 81t

Migraine, 5:51

Milch technique, 22:259–260, 260t

Mild traumatic brain injury, 11:121–128
ACEP clinical policy on CT scan criteria, 11:124, 124t, 127
admission criteria, 11:127
Canadian CT Head Rule, 11:124–125, 124t, 127
definition of, 11:122
discharge criteria, 11:127
discharge instructions, 11:127
history in, 11:122–123
laboratory evaluation of, 11:125
management of, 11:125–126
mechanism of injury, 11:122–123
New Orleans Criteria, 11:124–125, 124t, 127
physical findings, 11:123
radiographic indications, 11:123–125
resuming sports activities after, 11:127
signs and symptoms of, 11:123, 123t

Miliaria, 4:38–39

Miliaria crystalline, 4:38–39

Miliaria rubra, 4:39, 39f

Minerals, 20:240, 241

“Mirror image” burns, 25:293

Mistletoe, 20:238

Modified Barium swallow (MBS) study, 24:285, 285f

Mondor's disease, 9:99

“Mongolian spots,” 25:295

Monistat (miconazole), 4:41t

Montelukast (Singulair), 16:186t, 188t, 190

“Morning-after pill,” 15:178

Morphine (MS Contin)
equianalgesic dosing, 5:53t
equipotent opioid conversions, 10:115, 115t
for pediatric pain management, 7:78, 78t
for tachypnea, 10:116

Motor rehabilitation, 24:283–284, 283f

Motor vehicle collisions (MVCs), 12:133

Mount Everest, 13:145

MPI. *See* Myocardial perfusion imaging

MRCP. *See* Magnetic retrograde cholangiopancreatography

MRI. *See* Magnetic resonance imaging

MS Contin (morphine), 5:53t

Multi-detector computed tomogra-
phy (MDCT), 18:213–214

Multisystem trauma, 23:271

Munchausen syndrome by proxy, 25:294

Mupirocin, 4:44

Muscle relaxants, 5:50t

***Mycoplasma pneumoniae* infection**, 17:201

Myocardial infarction, 3:26–27
acute, 18:209
annual rates, 3:31f
classification of, 18:211, 211t
non-ACS, 18:211

Myocardial perfusion imaging, 3:25–34, 26f, 27f, 28f
dual isotope studies, 3:33
effective doses, 3:33
exercise tests, 3:27f, 29
false-negative stress tests, 3:29t, 30
normal studies, 3:27–28, 27f
radiation from, 3:33
recommended uses, 3:32–33, 32f
rest views, 3:27f, 29
risk stratification, 3:31–32
stress tests, 3:28f, 29–30
typical doses, 3:33

Myoview® (tetrofosmin), 3:28

Myxedema, 2:18, 21

N

Nalbuphine (Nubain), 7:78, 78t

Naloxone (Narcan)
with buprenorphine (Suboxone®), 14:159
for pediatric buprenorphine overdose, 14:160
for pediatric pain management, 7:79

Naproxen (Naprosyn), 7:77, 77t

Narcan (naloxone), 7:79

Narcotic pain relievers, 5:50t

National Asthma Education Program (NAEP) Expert Panel, 16:189

National Center for Complementary and Alternative Medicine (NCCAM), 20:236

National Emergency X-Radiography Utilization Study (NEXUS), 12:134, 135, 135t

National Heart, Lung, and Blood Institute (NHLBI), 16:183, 185t

National Institute for Health and Care Excellence (NICE), 24:282

National Institutes of Health (NIH), 20:236

National Pain Centre, 5:52t

NCCAM. *See* National Center

for Complementary and Alternative Medicine

Nebulizers, 16:187

Neck trauma

anteroposterior view, 12:137, 138f
cross-table lateral view, 12:136–137, 137f

discharge criteria for, 12:138–139
flexion and extension views, 12:138
history in, 12:133
management of, 12:138

minor, 12:133–139

oblique views, 12:137

odontoid view, 12:137, 137f

physical examination in, 12:133–134

plain radiographs of, 12:136–138

pre-hospital treatment of, 12:138

radiographic evaluation of, 12:136

spinal cord level, 12:136–137, 137f

swimmer's lateral view, 12:137–138

Necrotizing pneumonia, 17:205, 205f

Neglect

of children, 25:289

definition of, 25:289

risk factors for, 25:290

Neisseria gonorrhoeae, 15:176

Neonatal herpes, 4:45

Neonatal pneumonia, 17:197–199, 200

Neonatal rashes, 4:38–41

Neonatal scabies, 4:40–41

Nephropathy, contrast-induced, 18:214

Nephrotic syndrome, 2:16, 20

New Orleans Criteria, 11:124–125, 124t, 127

Newborns. *See under* Neonatal

Next Choice (levonorgestrel), 15:176, 177t

NEXUS. *See* National Emergency X-Radiography Utilization Study

Niacin (vitamin B3), 20:240

NIDA, 5:52, 52t

Nifedipine, 13:150t, 151, 152

NIH. *See* National Institutes of Health

Nitrates, 20:238

Nitric oxide, inhaled, 16:191

Nitrous oxide (N₂O), 7:81, 81t

Nizoral (ketoconazole), 4:41t

Nodules, 4:38t

Nonsteroidal anti-inflammatory drugs (NSAIDs), 7:77, 77t, 78t

Norco (acetaminophen/hydrocodone)

equianalgesic dosing, 5:53t

for pediatric pain management, 7:77t

Nordette (progestin and estrogen), 15:177t

Norgestrel

for dysfunctional uterine bleeding, 15:172t

for emergency contraception, 15:177t

NSAIDs. *See* Nonsteroidal anti-inflammatory drugs

Nubain (nalbuphine), 7:78, 78t

Nuclear medicine, 3:25

Nuclear myocardial perfusion imaging, 3:32–33, 32f

Nutrition, 6:67

Nutritional supplements, 20:233–242

Nystatin (Mycostatin), 4:41t, 42

O

OCPs. *See* Oral contraceptive pills

Odontoid view, 12:137, 137f

Ofloxacin, 15:176

Ogestrel (combination progestin and estrogen), 15:177t

OI. *See* Osteogenesis imperfecta

Older adults

head injuries in, 23:276

RSV in, 26:303–304

winter sports injuries among, 23:276
“187 Fake Cancer ‘Cures’

Consumers Should Avoid” (FDA), 20:239

Opiates, 7:78, 78t

Opioid agreements, 5:52, 56

Opioid Risk Tool (ORT), 5:52, 52t

Opioid tolerance, 5:52

Opioids

equianalgesic dosing, 5:52–54, 53t

equipotent conversions, 10:115, 115t

for pain management, 5:54–55

for pain management at end of life, 5:56–57

for palliative care pain management, 5:56–57

for pediatric pain management, 7:77–79, 77t, 78t

prescribing guidelines for, 5:55t
use/abuse of, 5:49–58, 52t

Oral anticoagulants, 14:163–165

Oral contraceptive pills (OCPs)

for dysfunctional uterine bleeding, 15:172t

for emergency contraception, 15:176, 177t

Organ failure, 10:111

Orfacial injuries, 25:294

ORT. *See* Opioid Risk Tool

Orthopedic injuries, 22:261–262

Orthoses, ankle-foot (AFO), 24:284

Oseltamivir (Tamiflu), 17:203

Osteogenesis imperfecta (OI), 25:295–296

Oucher scale, 7:73

“Ouchless” ED, 7:82

Outpatient pediatric skin rashes, 4:37–46

Overdose, drug, 5:50–51

Overuse injuries, 23:273

Oxycodone (OxyContin)

abuse of, 5:50, 50t

acetaminophen/oxycodone

(Percocet), 5:53t, 7:77t

equianalgesic dosing, 5:53t

equipotent opioid conversions, 10:115t

for pediatric pain management, 7:78

“Oxy-free,” 5:56

Oxygen partial pressure (PO₂), 13:147

Oxygen therapy

for acute severe asthma, 16:186, 186t

for community-acquired pneumonia in children, 17:203

for high-altitude illness, 13:150t, 152–153

for high-altitude pulmonary edema, 13:150

P

Packed red blood cells (PRBC), 14:164, 165

Pain

acute chest pain, 18:209–219

breakthrough, 5:52

cancer, 5:51

chronic, 5:51, 51t, 56

as fifth vital sign, 7:73

knee, 5:51

low back, 5:51

in pediatric patients, 7:73–83

Pain assessment, 7:73–74

Pain management

at end of life, 5:56–57

gate theory of, 7:76

with opioids, 5:54–55

palliative care, 5:56–57

in pancreatitis, 6:66

in pediatric patients, 7:73–83

for rib fractures, 12:140

Pain relievers, 5:50t

Palivizumab, 26:306t, 308, 309

Palliative care

barriers to, 10:116, 116t

case example, 10:116–117

core competencies, 10:110, 111t

definition of, 10:109, 111
in ED, 10:109–118
Education in Palliative and End-of-Life Care for Emergency Medicine (EPEC-EM), 10:110
emergency, 10:109–110, 116–117
management of patients in, 5:56–57
Rapid Palliative Care Assessment, 10:112, 112t, 114, 116
Panax ginseng (Asian ginseng), 20:238
Panax quinquefolius (American ginseng), 20:238
Pancreatitis, 6:61–71
acute, 6:64t, 67t
chronic, 6:68–69
CT Severity Index (CTSI) for, 6:64
Ranson’s criteria for, 6:63t, 64, 65
Pancreatography, 6:67
Pantothenic acid (vitamin B), 20:240
Papules, 4:38t
Paraphimosis, 9:104–105
Paraphimosis mimics, 9:105
Parapneumonic effusions (PPE), 17:204–205, 204f
Partial pressure of inspired oxygen (PIO₂), 13:145, 146t, 147
Partial pressure of oxygen (PO₂), 13:147
Patches, 4:38t
PBA. *See* Pseudobulbar affect
PCC. *See* Prothrombin complex concentrates
PCOS. *See* Polycystic ovarian syndrome
PE. *See* Pulmonary embolism
Peak expiratory flow rate (PEFR), 16:184
Pediatrics. *See* Children
PEFR. *See* Peak expiratory flow rate
Penetrating trauma
criteria for ED thoracotomy, 19:221
with recent loss of signs of life, 19:221
Penicillin, 15:175t
Penile anatomy, 9:97–98, 103f
Penile dorsal nerve block, 9:103
Penile fracture injury, 9:97–99, 98f
activities associated with, 9:98, 99t
Penile zipper injuries, 9:104, 104f
Penny pincers, 1:8
Pennyroyal, 20:238
Percocet (acetaminophen/oxycodone)
equianalgesic dosing, 5:53t
for pediatric pain management, 7:77t
Perfusion imaging, myocardial, 3:25–34, 26f, 27f, 28f
Pericardial tamponade, 19:221–222
Pericarditis, constrictive, 2:15–16, 20
Peripheral edema
case examples, 2:13
causes of, 2:15, 15t, 16f
clinical presentation of, 2:15, 16f
differential diagnoses, 2:15–19, 16f
evaluation of, 2:13–23
history taking in, 2:19–21, 19t
idiopathic, 2:18–19, 21
management of, 2:21–22
pathophysiology of, 2:14–15
patient disposition in, 2:21–22
physical examination in, 2:19–21
physical findings, 2:17t
Permethrin, 4:41
Petasites hybridus (butterbur), 20:237
Petechiae, 4:38t
Phalanx fractures
management of, 21:252
splints for, 21:252, 252t
Phalanx injuries, 21:250–251
Pharmacologic anxiolysis, 7:80–81
Phenylephrine, 9:103
Phimosis, 9:104–105
Phosphodiesterase (PDE) inhibitors
drug interactions, 20:238
for high altitude illness, 13:151–152
Physical abuse
of children, 25:289–299
definition of, 25:289
sequelae of, 25:290
Physical examination
adolescent gynecologic exam, 15:170
in evaluation for child abuse, 25:294–295
tests for skier’s thumb, 21:249
Physiology, 2:14
Pike’s Peak, 13:145
Pill Mill Crackdown Act of 2011 (H.R. 1065), 5:51
Pill Mill Crackdown Act of 2011 (S. 1760), 5:51
Pill mills, 5:51
Pincer grasp testing, 21:249
Pitting edema, 2:20
Pityriasis rosea (PR), 4:43
Pivot shift test, 23:270
Plain film radiography, 12:136–137, 137f, 138f
Plan B (levonorgestrel), 15:176, 177t
Plaques, 4:38t
Pneumatocele, 17:204f, 205
Pneumonia
aspiration, 17:201
bacterial, 17:198t, 199, 200–201, 201t
in children, 17:197–206, 198t, 199t, 200t, 201, 201t
community-acquired, 17:197–206, 198t, 199t, 200t
epidemiology of, 17:197
etiology of, 17:197
necrotizing, 17:205, 205f
in neonates, 17:197–199, 200
viral, 17:199, 200, 201t, 203
Poison Control Centers (PCCs), 14:158
Polycystic ovarian syndrome (PCOS), 15:171
Polymerase chain reaction, 17:202
Positive end-expiratory pressure (PEEP)
for acute severe asthma, 16:191
auto-PEEP, 16:182–183, 190
intrinsic (PEEPi), 16:182–183
Post-concussive syndrome, 11:126
Posterior rib fractures, 25:292, 292f
Posterior urethral injuries, 9:100–101
PPE. *See* Parapneumonic effusions
PR. *See* Pityriasis rosea
PRBC. *See* Packed red blood cells
Prednisone, 16:186
Pregnancy
peripheral edema in, 2:18, 20–21
physiologic changes with altitude, 13:146–147
teen, 15:176
Premarin, 15:172t
Prescription drug abuse
prevalence of, 5:49, 50–51, 50t
screening tools for, 5:52t
Priapism, 9:102–104, 102t
Priapus, 9:102
Prilocaine
EMLA (eutectic mixture of lidocaine and prilocaine), 7:79t, 80
for pain management in pediatric patients, 7:79t
Primary Stroke Centers, 24:282
Primatene®, 20:238
Procaine, 7:79t
Prochlorperazine, 13:150t, 152
The Professional’s Handbook of Complementary and Alternative Medicines, 20:236
Progesterone, 15:176
Progestin, 15:177t
Promethazine, 13:152
Propranolol overdose, 14:161
Prothrombin complex concentrates (PCC)
for oral anticoagulant overdose, 14:165
for rapid reversal of INR, 11:126
Proximal interphalangeal joint (PIP) dislocation, 21:251–252, 251f
Proximal thumb metacarpal fractures, 21:245

Pseudoaddiction, 5:54t, 55
Pseudobulbar affect (PBA), 24:286
Psoriasis, 4:41
Psychological stroke recovery, 24:285–286
Psychosocial issues
evaluation of suspected child abuse, 25:296
after stroke, 24:286
Pulmonary edema
high-altitude pulmonary edema (HAPE), 13:145, 147–148, 148t, 150–151, 150t
physical findings, 2:17t
Pulmonary embolism (PE)
fibrinolytics for, 19:224–225
massive, 19:224
Pulmonary hypertension
and high altitude, 13:147, 147t
peripheral edema with, 2:16–17
Purple coneflower (*Echinacea purpurea*), 20:239
Purpura, 4:38t
Pustules, 4:38t
Pyridoxine (vitamin B6), 20:240

Q

Quality of life, 10:110

R

“Raccoon eyes,” 25:294
Race differences, 25:289–290
Radial gutter splints, 21:253f
Radiation exposure
with CT scanners, 18:214
with nuclear myocardial perfusion imaging, 3:33
Radiography
of cervical spine, 12:136–137, 137f, 138f
indications for chest radiography, 12:139–140
indications for chest radiography in children, 17:201t, 202
of minor neck trauma, 12:136
of pediatric foreign body ingestions, 1:1, 2f
plain film, 12:136–137, 137f, 138f
of scaphoid fractures, 21:247, 247f
“scaphoid” or “navicular” view, 21:248
of shoulder dislocation, 22:262–263, 263f
of skier’s thumb, 21:249–250, 249f
of subungual hematomas, 21:250, 251f
of Tuft fractures, 21:250, 250f

of urethral injuries, 9:100f, 101
Radionuclide imaging, 3:32
Radiotracers, 3:25, 28
R-albuterol (levalbuterol or Xopenex®), 16:187
Ranson’s criteria, 6:63t, 64, 65
Rapid Palliative Care Assessment, 10:112, 112t
case example, 10:114, 116
Rashes
outpatient pediatric skin rashes, 4:37–46
scaly, 4:43–44
vesicular, 4:44–45
***Rauwolfia serpentina* (Indian snake-root)**, 20:239
RCA. *See* Right coronary artery
RDA. *See* Recommended daily allowance
Reactive airway disease
history of, 17:201
RSV association with, 26:302
Recombinant factor VIIa (rFVIIa)
for oral anticoagulant overdose, 14:164, 165
for rapid reversal of INR, 11:126
Recommended daily allowance (RDA), 20:240
Red yeast rice, 20:239
Regadenoson (Lexiscan®) stress tests, 3:31
Regional rashes, 4:41
Regulation, 20:233–236
Rehabilitation
cognitive rehabilitation, 24:285
motor rehabilitation, 24:283–284, 283f
speech and language, 24:284–285
stroke rehabilitation, 24:282
Relenza (zanamivir), 17:203
Repetitive transcranial magnetic stimulation (rTMS), 24:284
Resistant *Neisseria gonorrhoeae*, 15:176
Respiratory distress, pediatric, 17:200, 200t
Respiratory failure
acute, 16:191
secondary to status asthmaticus, 16:191
Respiratory syncytial virus (RSV), 26:301, 304f
Respiratory syncytial virus (RSV) infection, 26:301–311
in adults, 26:301–302, 303–304, 305, 306t, 308–309
in elderly, 26:303–304

evaluation of, 26:307f
in infants and children, 26:301, 303, 304–305, 305–308, 306t, 307f
management of, 26:305–308
seasonal duration, 26:301, 303f
seasonal variation, 26:301, 304f
treatment options, 26:306t
vaccination against, 26:307–308
Restrictive cardiomyopathy, 2:15–16, 20
Resuscitation, acute, 10:112
Retepase
dosing, 19:226t
for pulmonary embolism, 19:225
Retinal hemorrhage, 25:293, 296
Retinopathy, high-altitude, 13:153
Reverse Hill-Sachs lesion, 22:261, 262f
Rib fractures
admission criteria, 12:140–141
in children, 25:292, 292f
history of, 12:139
indications for chest radiograph, 12:139–140
management of, 12:140
posterior, 25:292, 292f
Ribavirin, 26:306–307, 306t, 309
Riboflavin (vitamin B2), 20:240
Right coronary artery (RCA), 3:26
Rigid chest syndrome, 7:78
Risk Evaluation and Mitigation Strategies (REMS), 5:51–52
Rivaroxaban overdose, 14:163, 164, 165
Robot-assisted training, 24:284
Rolando fractures, 21:249, 249f
Roxicodone, 5:53t
RSV. *See* Respiratory syncytial virus
rTMS. *See* Repetitive transcranial magnetic stimulation

S

S. 1760: Pill Mill Crackdown Act of 2011, 5:51
S100B, 11:125
S-albuterol, 16:187
Saline, hypertonic, 26:306, 306t
Salmeterol
for high-altitude illness, 13:150t, 152
for high-altitude pulmonary edema, 13:151
***Sanguinaria canadensis* (blood root)**, 20:239
Saxagliptin, 14:162
Scabies
infantile, 4:40, 41f
neonatal, 4:40–41

- Scale, 4:39t
- Scaly rashes, 4:43–44
- Scaphoid fractures, 21:245, 247–248
mechanism of, 21:247, 247f
radiography of, 21:247, 247f
splint for, 21:252t
treatment system for, 21:248
- Scaphoid tubercle tenderness, 21:247
- Scapular manipulation, 22:260, 260t
- SCD. *See* Sickle cell disease
- Scopolamine, 10:115–116
- Scorpion bites, 6:62
- Screeener and Opioid Assessment for Patients with Pain (SOAPP/SOAPP-R), 5:52, 52t
- Screening tools
for abuse potential, 5:52, 52t
samples for clinical use, 5:52t
- Screening toxicology, 5:52
- Scrotal gangrene, Fournier's, 8:85, 87f
- Seasonale (progesterin and estrogen), 15:177t
- Seasonique (progesterin and estrogen), 15:177t
- Seborrheic dermatitis, neonatal, 4:39–40, 40f
- Secretions, terminal, 10:115–116
- Sedation, deep, 7:81–82
- Sedatives, 7:81t
- Selenium, 20:240, 241
- Selenium overdose, 20:241
- Selenium sulfide lotion, 4:43
- Serious bacterial infection (SBI), 26:305
- Serotonin syndrome, 20:239
- Sestamibi (Cardiolite®), 3:28, 30, 33
- Sexual abuse, 25:296
- Sexually transmitted infections (STIs), 15:173–176
management of, 15:173, 174t–175t
- “Shaken-baby syndrome,” 25:293
- Shock, hemorrhagic, 19:222
- Shot blocker instruments, 7:76
- Shoulder, 22:257
- Shoulder dislocation, 22:257–266
anterior, 22:258, 258f, 259f
associated injuries, 22:261–262, 261t, 262
follow-up care, 22:264
imaging of, 22:262–264, 262f, 263f, 264f
posterior, 22:258, 261f, 262f, 263f, 264f
recommendations for, 22:264
recurrence of, 22:258, 258t, 264
types of, 22:258–259, 259t
- Shoulder injuries
dislocation, 22:257–266
in downhill skiing, 23:270–271, 271t
in snowboarding, 23:271t, 272
- Shoulder relocation, 22:260–261
Cunningham technique for, 22:260, 260t
Eskimo technique, 22:260t, 261
Hippocratic method, 22:260, 260t
leverage methods, 22:259–260
Milch technique, 22:259–260, 260t
reduction techniques, 22:259
Spaso technique, 22:260, 260t
Stimson method, 22:260, 260t
techniques for, 22:260t
- Shoulder traction, 22:260–261
Hippocratic method, 22:260
techniques for, 22:261
- Siberian ginseng (*Eleutherococcus senticosus*), 20:238
- Sickle cell disease
community-acquired pneumonia in children with, 17:199
physiologic changes with altitude, 13:146–147, 147t
- Signs of life, 19:221
- Sildenafil, 13:150t, 151–152
- Single-photon emission computed tomography
gated imaging, 3:30
normal studies, 3:27–28, 27f
- Singulair (montelukast), 16:188t
- Sitagliptin (Januvia™)
adverse effects of, 14:162
overdose of, 14:162–163
- Skeletal fractures, 25:295
- Skeletal injuries, 25:292
- Skeletal muscle, 18:209
- Skier's thumb, 21:245, 249–250, 249f, 23:270–271, 273
- Skiing
cross-country skiing injuries, 23:272t, 273–274
downhill skiing injuries, 23:270–271
- Skin rashes
diagnosis of, 4:38
distribution/configuration of, 4:38
evaluation of, 4:37–38
history taking in, 4:37
neonatal, 4:38–41
pediatric, 4:37–46
primary lesions, 4:37–38, 38t
regional, 4:41
secondary lesions, 4:38, 39t
- Skull fractures, 25:292
- SLAP (Superior Labral tear, Anterior to Posterior), 22:261
- Slate-gray spots, 25:295
- Sledding, 23:275
- Sledding injuries, 23:275–276
- “Snow blindness,” 13:153
- Snowbird technique, 22:260–261
- Snowboarding, 23:271
- Snowboarding injuries, 23:271–273
clavicle fractures, 23:272–273
head injuries, 23:271–272, 271t
shoulder injuries, 23:271t, 272
wrist injuries, 23:272
- Snowmobiling injuries, 23:275
- Snuff box tenderness, 21:247
- SOAPP/SOAPP-R. *See* Screeener and Opioid Assessment for Patients with Pain
- Sodium bicarbonate, 7:79–80
- Soft-tissue injury
non-specific, 12:138
plain radiographic assessment of, 12:137
- Speech and language rehabilitation, 24:284–285
- Sphincter of Oddi dysfunction, 6:69
- Spinal cord injury
in downhill skiing, 23:271
incidence of, 12:133
level of injury, 12:133–134, 134f, 136–137, 137f
radiographic indications, 12:134–135
spinal cord level of injury, 12:133–134, 134f, 136–137, 137f
- Splinting
aluminum foam finger splint, 21:252, 252f
for hand and wrist injuries, 21:252t, 253
radial gutter splints, 21:253f
thumb spica splint, 21:248, 248f
types of splints, 21:252, 252t
ulnar gutter splints, 21:253f
- Sports injuries
resuming activities after, 11:127
winter sports injuries, 23:269–278
- SRS. *See* Summed Rest Score
- SS. *See* Serotonin syndrome
- SSS. *See* Summed Stress Score
- St. John's wort (*Hypericum perforatum*), 20:237, 239
- Starling forces, 2:14, 14f
- Starvation, 25:294
- Status asthmaticus
definition of, 16:181
refractory, 16:191
respiratory failure secondary to, 16:191
treatment of, 16:191

Stemmer sign, 2:21

Steroids. *See* Corticosteroids

Stimson method, 22:260, 260t

STIs. *See* Sexually transmitted infections

Streptokinase
dosing, 19:226t
for pulmonary embolism, 19:225

Stress tests, 3:29–30, 18:209
adenosine, 3:31
dobutamine, 3:30–31
false-negative, 3:29t, 30
regadenoson (Lexiscan®), 3:31
technetium-99m-sestamibi, 3:28f, 29

Stroke recovery, 24:281–287
grading system for, 24:282, 283t

Stroke rehabilitation, 24:282
cognitive rehabilitation, 24:285
motor rehabilitation, 24:283–284
speech and language rehabilitation, 24:284–285

Subdiaphragmatic hemorrhage, 19:222

Subdural hematoma, 23:272, 272f

Sublimaze (fentanyl), 5:53t

Suboxone® (naloxone with buprenorphine), 14:159

Substance abuse, 5:55

Subungual hematomas, 21:250, 251f

Subutex® (sublingual buprenorphine), 14:159

Sucrose, 7:77, 77t

Sudden death, 10:111, 112

Summed Rest Score (SRS), 3:29

Summed Stress Score (SSS), 3:29, 29t

Supplement labels, 20:234

Supplements
cardiovascular toxicity, 20:238–239
complications of, 20:233–242
Current Good Manufacturing Practices for, 20:235
gastrointestinal toxicity, 20:237–238
hematologic toxicity, 20:238–239
herbal, 20:236–237
in medicine, 20:236
regulation of, 20:233–236
resources for, 20:236

Surgery
for pancreatitis, 6:68
for urethral injuries, 9:101

Swimmer’s lateral view, 12:137–138

Symphytum officinale, *Symphytum asperum*, and *Symphytum x uplandicum* (comfrey), 20:237

Synalar (fluocinolone acetonide), 4:40t

Syphilis, 15:175t

T

TAC (tetracaine, adrenaline, and cocaine), 7:79t, 80

Tachypnea, 10:116

Tadalafil, 13:150t, 151–152

Tamiflu (oseltamivir), 17:203

Taping, finger buddy, 21:253f

Taqaandan (or taghaandan), 9:98

TBI. *See* Traumatic brain injury

tDCS. *See* Transcranial direct current stimulation

Technetium-99m, 3:27–28
typical doses, 3:33

Technetium-99m-sestamibi stress tests, 3:28f, 29

Teen pregnancy, 15:176

Temazepam, 13:150t, 152

Temovate (clobetasol propionate), 4:40t

Tenderness
scaphoid tubercle, 21:247
snuff box, 21:247

Tenecteplase
dosing, 19:226t
for pulmonary embolism, 19:225

Terbinafine (Lamisil), 4:41t

Terbutaline, 16:188t

Terminal illness
avoiding ED transfer in, 10:113–114
common presentations, 10:112–113
ED deaths of patients with, 10:113
trajectory for ED patients, 10:111, 112

Terminology
for primary lesions, 4:38t
for secondary lesions, 4:39t

“**Test boluses**,” 18:214

Testicles, 8:91–92, 91f

Testicular appendage torsion, 8:89–90, 89f

Testicular torsion, 8:90–92, 91f

Tetracaine, 7:79t, 80

Tetrofosmin (Myoview®), 3:28, 33

Thallium scans, 3:28

Thallium-201, 3:27–28
typical doses, 3:33

Theophylline
for acute severe asthma, 16:189
for high altitude illness, 13:152

Thiamin (vitamin B1), 20:240

Thoracotomy, emergency department, 19:221–223
indications for, 19:223t
survivability, 19:223, 224t
3-vessel disease, 3:30

Thumb, 21:247–248

Thumb axis injuries, 21:245–246

Thumb dislocation, 21:251–252, 251f

Thumb injuries
proximal thumb metacarpal fractures, 21:245
skier’s thumb injuries, 21:245, 249–250, 249f, 23:270–271, 273

Thumb metacarpal fractures, 21:245, 248–249
splint for, 21:252t

Thumb spica splint, 21:248, 248f

Thumb sprains, 23:273

Tinactin (tolnaftate), 4:41t

Tinea, 4:42–43

Tinea capitis, 4:42

Tinea corporis, 4:42, 43f

Tinea cruris, 4:42

Tinea pedis, 4:42

Tinea versicolor, 4:43, 43f

Tolnaftate (Tinactin), 4:41t

Topical anesthetics, 7:80

Topical antifungal drugs, 4:41t

Topical corticosteroids, 4:39–40, 40t

Toradol (ketorolac), 7:78t

Torsion
testicular, 8:90–92, 91f
testicular appendage, 8:89–90, 89f

Toxicology, 14:157–167
screening, 5:52

Traction, 22:260–261
Eskimo technique, 22:260t, 261
shoulder, 22:260–261
Spaso technique, 22:260, 260t
Stimson method, 22:260, 260t

Traction/counter-traction, 22:260, 260t

Traditional Chinese medicine, 20:234–235

Tramadol (Ultram)
equianalgesic dosing, 5:53t
for pediatric pain management, 7:78–79, 78t

Transcranial direct current stimulation (tDCS), 24:284

Transcranial magnetic stimulation, 24:283, 283f
repetitive (rTMS), 24:284

Transdermal fentanyl (fentanyl patch), 5:53t

Transfers, ED, 10:113–114

Transmucosal fentanyl (Actiq), 5:53t

Trauma
abusive head trauma (AHT), 25:293
acute, 23:273
blunt, 19:221

chest trauma, 12:139–141
CNS, 25:292–293, 296
in cross-country skiing, 23:273
inflicted traumatic brain injury, 25:293
mild traumatic brain injury, 11:121–128
minor, 11:121–130, 12:133–142
multisystem, 23:271
neck trauma, 12:133–139
penetrating, 19:221
red flags for abuse, 25:294–295, 295t
Traumatic brain injury
definition of, 11:121
inflicted, 25:293
mild, 11:121–128
Treadmill training, 24:283
Trephination, 21:250–251
Triamcinolone, 4:44
Triamcinolone acetonide (Aristocort HP, Elocon, Kenalog), 4:40t
Triazolam, 13:152
Trichomonas, 15:174t–175t
“Triple rule out” CT angiography (TRO-CTA), 18:214–215
Troponins
cardiac troponin assays, 18:209–210
high-sensitivity cardiac troponin (hs-cTn), 18:209–211
non-ischemic of elevation of, 18:211, 211t
in skeletal and cardiac muscle, 18:209
Trypsinogen activation peptide (TAP), 6:64
Tuft fractures, 21:250, 250f
Tumors, 4:38t
Tylenol (acetaminophen), 7:77t, 78

U
UA. See Unstable angina
UCL. See Ulnar collateral ligament
Ulcers, 4:39t
Ulipristal acetate (UPA, Ella), 15:176, 177t, 178
Ulnar collateral ligament (UCL) injury, 21:249
Ulnar deviation, 21:247
Ulnar gutter splints, 21:253f
Ultram (tramadol)
equianalgesic dosing, 5:53t
for pediatric pain management, 7:78–79, 78t
Ultrasound
endoscopic, 6:67–68
point-of-care, 22:263
of shoulder dislocation, 22:263,

263f, 264f
Ultraviolet keratitis, 13:153
United States
CAM use in, 20:233, 235f
spending on herbal supplements, 20:233
supplements used in, 20:236t
Unstable angina (UA), 18:209
UPA (ulipristal acetate), 15:176, 178
Upper extremity fractures, 21:245
UpToDate.com, 20:236
Urethra, adult male, 9:99–100
Urethral injuries, 9:99–102, 100f
AAST organ injury scale, 9:101, 101t
radiographic imaging of, 9:100f, 101
red flags for, 9:100, 100t
treatment of, 9:101–102
Urethroplasty, 9:101
Urokinase
dosing, 19:226t
for pulmonary embolism, 19:225
U.S. Preventive Services Task Force (USPSTF), 24:282, 283t
Uterine bleeding, dysfunctional (DUB), 15:171

V
Vaccination against RSV, 26:307–308
Vaginal bleeding, 15:170–173
Vaginosis, bacterial, 15:174t
Valacyclovir, 15:174t
Valisone (betamethasone valerate), 4:40t
Valium (diazepam), 7:80–81, 81t
Vapocoolant sprays (cold sprays), 7:76, 80
Varicella zoster virus (VZV), 4:44–45, 44f
Venous insufficiency/venous occlusion
history and physical examination, 2:21
peripheral edema with, 2:16
Ventilation
high-frequency oscillatory, 16:191
mechanical, 16:190–191
Versed (midazolam), 7:80–81, 81t
Vesicles, 4:38t
Vesicular rashes, 4:44–45
Vicodin (hydrocodone combination), 5:53t
Violence, 12:133
Viral pneumonia, 17:199, 200, 201t, 203
Vital signs, fifth, 7:73
Vitamin A, 20:240
Vitamin B (pantothenic acid), 20:240
Vitamin B1 (thiamin), 20:240

Vitamin B2 (riboflavin), 20:240
Vitamin B3 (niacin), 20:240
Vitamin B6 (pyridoxine), 20:240
Vitamin B12, 20:240
Vitamin C, 20:240
Vitamin D, 20:240, 241
Vitamin E, 20:240–241
Vitamin K
for rapid reversal of INR, 11:126
side effects of, 20:240
Vitamins, 20:240–241
Volatile anesthetics, 16:191
Voluntary distraction, 7:76

W
Warfarin, 11:125–126
Washington Emergency Department Opioid Prescribing Guidelines, 5:55t, 56
Weight gain, 2:18
Westcort (hydrocortisone valerate), 4:40t
Western Trauma Association, 19:221–222
Wheals, 4:38t
Whiplash injury, 12:133
Whitlow, herpetic, 4:45, 45f
Willow bark, 20:238–239
Winter sports injuries, 23:269–278
Wong Baker Face scale, 7:73
World Health Organization (WHO)
analgesic ladder for cancer pain, 5:56
definition of acute myocardial infarction, 18:209
Wrist injuries, 21:245–254
in snowboarding, 23:272
Wuchereria bancrofti, 2:18

X
Xopenex® (R-albuterol), 16:187

Y
Yeast infection, 15:174t
Yuzpe regimen
contraindications to, 15:178
for emergency contraception, 15:176

Z
Zafirlukast, 16:190
Zanamivir (Relenza), 17:203
Zero position, 22:259
Zinc, 20:240, 241
Zipper injuries, penile, 9:104, 104f
Zolpidem, 13:150t, 152

Dear *Emergency Medicine Reports* Subscriber:

This issue of your newsletter marks the start of a new continuing medical education (CME) semester and provides us with an opportunity to remind you about **the procedures for earning CME and delivery of your credit letter**.

Emergency Medicine Reports, sponsored by AHC Media, provides you with evidence-based information and best practices that help you make informed decisions concerning treatment options and physician office practices. Our intent is the same as yours — the best possible patient care.

Upon completion of this educational activity, participants should be able to:

- recognize specific conditions in patients presenting to the emergency department;
- apply state-of-the-art diagnostic and therapeutic techniques to patients with the particular medical problems discussed in the publication;
- discuss the differential diagnosis of the particular medical problems discussed in the publication;
- explain both the likely and rare complications that may be associated with the particular medical problems discussed in the publication.

The American Medical Association, which oversees the Physician's Recognition Award and credit system and allows AHC Media to award *AMA PRA Category 1 Credit™*, has changed its requirements for awarding *AMA PRA Category 1 Credit™*. Enduring materials, like this newsletter, are now required to include an assessment of the learner's performance; the activity provider can award credit only if a minimum performance level is met. AHC Media considered several ways of meeting these new AMA requirements and chose the most expedient method for our learners.

HERE ARE THE STEPS YOU NEED TO TAKE TO EARN CREDIT FOR THIS ACTIVITY:

1. Read and study the activity, using the provided references for further research.
2. Log on to www.cmecity.com to take a post-test; tests can be taken after each issue or collectively at the end of the semester. *First-time users will have to register on the site using the 8-digit subscriber number printed on their mailing label, invoice, or renewal notice.*
3. Pass the online tests with a score of 100%; you will be allowed to answer the questions as many times as needed to achieve a score of 100%.
4. After successfully completing the last test of the semester, your browser will be automatically directed to the activity evaluation form, which you will submit online.
5. **Once the completed evaluation is received, a credit letter will be e-mailed to you instantly.** You will not have to wait to receive your credit letter!

This activity is valid 24 months from the date of publication. The target audience for this activity includes emergency medicine and family physicians.

If you have any questions about the process, please call us at (800) 688-2421, or outside the U.S. at (404) 262-5476. You can also fax us at (800) 284-3291, or outside the U.S. at (404) 262-5560. You can also email us at: customerservice@ahcmedia.com.

On behalf of AHC Media, we thank you for your trust and look forward to a continuing education partnership.

Sincerely,



Continuing Education Director
AHC Media